<SEC-DOCUMENT>0001171843-24-004904.txt : 20240823
<SEC-HEADER>0001171843-24-004904.hdr.sgml : 20240823
<ACCEPTANCE-DATETIME>20240822182429
ACCESSION NUMBER:		0001171843-24-004904
CONFORMED SUBMISSION TYPE:	POS AM
PUBLIC DOCUMENT COUNT:		5
FILED AS OF DATE:		20240823
DATE AS OF CHANGE:		20240822

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PORTAGE BIOTECH INC.
		CENTRAL INDEX KEY:			0001095435
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			D8
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		POS AM
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-275229
		FILM NUMBER:		241233096

	BUSINESS ADDRESS:	
		STREET 1:		CLARENCE THOMAS BUILDING
		STREET 2:		P.O. BOX 4649, ROAD TOWN
		CITY:			TORTOLA
		STATE:			D8
		ZIP:			VG1110
		BUSINESS PHONE:		416-737-7600

	MAIL ADDRESS:	
		STREET 1:		CLARENCE THOMAS BUILDING
		STREET 2:		P.O. BOX 4649, ROAD TOWN
		CITY:			TORTOLA
		STATE:			D8
		ZIP:			VG1110

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BONTAN CORP INC
		DATE OF NAME CHANGE:	20030421

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	DEALCHECK COM INC
		DATE OF NAME CHANGE:	19990921
</SEC-HEADER>
<DOCUMENT>
<TYPE>POS AM
<SEQUENCE>1
<FILENAME>posam_082224.htm
<DESCRIPTION>POS AM
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>As filed with the Securities and Exchange Commission on August 22, 2024</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Registration No. 333-275229</B></P>

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: black 2.25pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>UNITED STATES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>SECURITIES AND EXCHANGE COMMISSION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>WASHINGTON, D.C. 20549</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>POST-EFFECTIVE AMENDMENT NO. 1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>TO</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>FORM F-1</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>PORTAGE BIOTECH INC.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Exact name of Registrant as specified in its charter)</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><U>N/A</U></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Translation of Registrant&rsquo;s name into English)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>British Virgin Islands</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>2834</B></FONT></TD>
    <TD STYLE="width: 1%; text-align: center">&nbsp;</TD>
    <TD STYLE="width: 32%; border-bottom: black 1pt solid; text-align: center"><FONT STYLE="font-size: 10pt"><B>Not Applicable</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(State or other jurisdiction of<BR>
incorporation or organization)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(Primary Standard Industrial<BR>
Classification Code Number)</FONT></TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">(I.R.S. Employer<BR>
Identification No.)</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Clarence Thomas Building, P.O. Box 4649</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Road Town, Tortola</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>British Virgin Islands, VG1110<BR>
Telephone (203) 221-7378</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Address, including zip code, and telephone number, including area code,
of Registrant&rsquo;s principal executive offices)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Dr. Ian Walters c/o Portage Development Services, Inc.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>59 Wilton Road</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Westport, CT 06880</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Telephone (203) 221-7378</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">(Name, address, including zip code, and telephone number, including area
code, of agent for service)</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B><I>Copies to:</I></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Steven J. Abrams, Esq.</B></P>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Hogan Lovells US LLP</B></P>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>1735 Market Street, Suite 2300</B></P>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Philadelphia, PA 19103</B></P>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Telephone (267) 675-4600</B></P></TD>
    <TD STYLE="width: 50%">
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Karen Gilbert</B></P>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Forbes Hare LLP</B></P>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>5 King&rsquo;s Bench Walk</B></P>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Temple, London EC4Y 7DN</B></P>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>United Kingdom</B></P>
    <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Telephone +44 (0) 207 0143 225</B></P></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Approximate date of commencement of proposed sale to the public:</B> From time to time after
this registration statement is declared effective.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If any of the securities being registered on this Form are to be offered
on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, check the following box. &#9746;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If this Form is filed to register additional securities for an offering
pursuant to Rule 462(b) under the Securities Act, check the following box and list the Securities Act registration statement number of
the earlier effective registration statement for the same offering. &#9744;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to Rule 462(c)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. &#9744;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If this Form is a post-effective amendment filed pursuant to Rule 462(d)
under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective
registration statement for the same offering. &#9744;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Indicate by check mark whether the registrant is an emerging growth company
as defined in Rule 405 of the Securities Act of 1933.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: left; text-indent: 0.25in">Emerging growth company &#9744;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If an emerging growth company that prepares its financial statements in
accordance with U.S. GAAP, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. &#9744;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>The registrant hereby amends this registration statement on such date
or dates as may be necessary to delay its effective date until the registrant shall file a further amendment which specifically states
that this registration statement shall thereafter become effective in accordance with Section 8(a) of the Securities Act of 1933, as amended,
or until the registration statement shall become effective on such date as the Securities and Exchange Commission, acting pursuant to
said Section 8(a), may determine.</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>



<P STYLE="font-size: 10pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXPLANATORY NOTE</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">On October 31, 2023, the registrant filed a registration
statement on Form F-1 (Registration No. 333-275229), which was subsequently declared effective by the U.S. Securities and Exchange Commission
on November 7, 2023 (the &ldquo;<B>Registration Statement</B>&rdquo;).</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.1pt; margin: 0pt 0; background-color: white">This post-effective amendment
is being filed to update the Registration Statement to (i) incorporate by reference information contained in the registrant&rsquo;s annual
report on Form 20-F for the fiscal year ended March 31, 2024, filed with the SEC on August 14, 2024, and (ii) to update certain other
information in such Registration Statement. <FONT STYLE="background-color: white">The information included in this filing amends the Registration
Statement and the prospectus contained therein.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.1pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: -0.1pt; margin: 0pt 0; background-color: white">On August 15, 2024, the registrant
effected a reverse stock split at a ratio of 1-for-20 (the &ldquo;<B>Reverse Split</B>&rdquo;). As a result of the Reverse Split, every
twenty (20) pre-split ordinary shares were converted into one (1) post-split ordinary share. All share and per share numbers, option numbers,
warrant numbers, and other derivative security numbers and exercise prices appearing in this post-effective amendment have been adjusted
to give effect to the Reverse Split, unless otherwise indicated or unless the context otherwise suggests. However, the Company&rsquo;s
annual report and other reports and all other information and documents incorporated by reference into the Registration Statement that
were filed prior to August 15, 2024 do not give effect to the Reverse Split.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">No additional securities are being registered
under this post-effective amendment. All applicable registration fees were paid at the time of the original filing of the Registration
Statement.</P>

<P STYLE="font-size: 10pt; text-align: left; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: red">The information in this preliminary prospectus is not complete
and may be changed. The selling shareholders listed herein may not sell these securities until the registration statement filed with the
Securities and Exchange Commission is effective. This preliminary prospectus is not an offer to sell these securities and it is not soliciting
an offer to buy these securities in any state or jurisdiction where the offer or sale is not permitted.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0; color: red"><B>SUBJECT TO COMPLETION, DATED AUGUST <FONT STYLE="text-transform: uppercase">22,
2024</FONT></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>PRELIMINARY PROSPECTUS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Portage Biotech Inc.</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><IMG SRC="logo.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>481,581 Ordinary Shares underlying Warrants</B></P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The selling shareholders (the &ldquo;<B>Selling Shareholders</B>&rdquo;)
named in this prospectus may use this prospectus to offer and resell from time to time up to 481,581 of our ordinary shares, no par value
per share, consisting of (i) up to 157,895 ordinary shares (the &ldquo;<B>Series A Warrant Shares</B>&rdquo;), issuable upon the exercise
of warrants (the &ldquo;<B>Series A Warrants</B>&rdquo;), (ii) up to 157,895 ordinary shares (the &ldquo;<B>Series B Warrant Shares</B>&rdquo;)
issuable upon the exercise of warrants (the &ldquo;<B>Series B Warrants</B>&rdquo;), (iii) up to 157,895 ordinary shares (the &ldquo;<B>Series
C Warrant Shares</B>,&rdquo; together with the Series A Warrant Shares and the Series B Warrant Shares, the &ldquo;<B>Private Warrant
Shares</B>&rdquo;) issuable upon the exercise of warrants (the &ldquo;<B>Series C Warrants</B>,&rdquo; together with the Series A Warrants
and the Series B Warrants, the &ldquo;<B>Private Warrants</B>&rdquo;) issued in a private placement that closed on October 3, 2023 (the
&ldquo;<B>Private Placement</B>&rdquo;), pursuant to that certain Securities Purchase Agreement by and between us and certain of the Selling
Shareholders, dated as of September 29, 2023 (the &ldquo;<B>Securities Purchase Agreement</B>&rdquo;), and (iv) up to 7,896 ordinary shares
(the &ldquo;<B>Placement Agent Warrant Shares</B>,&rdquo; together with the Private Warrant Shares, the &ldquo;<B>Shares</B>&rdquo;) issuable
upon the exercise of warrants (the &ldquo;<B>Placement Agent Warrants</B>,&rdquo; together with the Private Warrants, the &ldquo;<B>Warrants</B>&rdquo;)
issued to the designees of the placement agent as compensation in connection with the Registered Direct Offering (defined below) and the
Private Placement.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Warrants were offered and sold without registration under the Securities
Act of 1933, as amended (the &ldquo;<B>Securities Act</B>&rdquo;), in reliance on the exemption provided by Section 4(a)(2) of the Securities
Act and Rule 506 of Regulation D promulgated thereunder. We are registering the offer and resale of the Shares to satisfy the provisions
of the Securities Purchase Agreement pursuant to which we agreed to register the resale of the Shares.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We are not selling any of our ordinary shares under this prospectus and
will not receive any of the proceeds from the sale of the Shares by the Selling Shareholders. We will, however, receive the net proceeds
of any Warrants exercised for cash.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Selling Shareholders may sell or otherwise dispose of the Shares covered
by this prospectus in a number of different ways and at varying prices. We provide more information about how the Selling Shareholders
may sell or otherwise dispose of the Shares covered by this prospectus in the section entitled &ldquo;Plan of Distribution&rdquo; on page
32. Discounts, concessions, commissions and similar selling expenses attributable to the sale of the Shares covered by this
prospectus will be borne by the Selling Shareholders. We will pay all expenses (other than discounts, concessions, commissions and similar
selling expenses) relating to the registration of the Shares with the Securities and Exchange Commission (the &ldquo;<B>SEC</B>&rdquo;).</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our ordinary shares are traded on the Nasdaq Capital Market under the symbol
&ldquo;PRTG.&rdquo; On August 21, 2024, the last reported sale price of our ordinary shares on the Nasdaq Capital Market was $2.65 per
share.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Investing in the securities offered in this prospectus involve a
high degree of risk. Before making any investment in these securities, you should consider carefully the risks and uncertainties in
the section entitled &ldquo;Risk Factors&rdquo; beginning on page 9 of this prospectus, and in the other documents that are
incorporated by reference into this prospectus. </B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Neither the Securities and Exchange Commission nor any state or non-U.S.
regulatory body has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus. Any representation
to the contrary is a criminal offense. </B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>The date of this prospectus is&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239;&#8239; &#9;, 2024</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B></B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>TABLE OF CONTENTS</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 89%; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt"><B>Prospectus </B></FONT></TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 8%; text-align: center"><FONT STYLE="font-size: 10pt"><B>Page<BR>
Number</B></FONT></TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; border-top: Black 1pt solid; padding-left: 10.1pt; text-indent: -10.1pt">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; border-top: Black 1pt solid; text-align: center">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">ABOUT THIS PROSPECTUS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; text-align: center">1</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">2</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">PROSPECTUS SUMMARY</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">3</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top"><FONT STYLE="font-size: 10pt">THE OFFERING</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">8</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">RISK FACTORS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">9</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">USE OF PROCEEDS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">15</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">DIVIDEND POLICY</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">15</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">SELLING SHAREHOLDERS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">16</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">CAPITALIZATION</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">18</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">DESCRIPTION OF SECURITIES BEING REGISTERED</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">19</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">TAXATION</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">26</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">PLAN OF DISTRIBUTION</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">32</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">EXPENSES</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">34</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">ENFORCEABILITY OF CIVIL LIABILITIES</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">35</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">LEGAL MATTERS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">37</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">EXPERTS</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">37</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">WHERE YOU CAN FIND MORE INFORMATION</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">37</TD></TR>
  <TR>
    <TD STYLE="vertical-align: top; padding-left: 10.1pt; text-indent: -10.1pt"><FONT STYLE="font-size: 10pt">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</FONT></TD>
    <TD STYLE="vertical-align: bottom">&nbsp;</TD>
    <TD STYLE="vertical-align: top; text-align: center">38</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 6; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>ABOUT THIS PROSPECTUS </B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This prospectus relates to the resale by the Selling Shareholders identified
in this prospectus under the caption &ldquo;Selling Shareholders,&rdquo; from time to time, of up to an aggregate of 481,581 of our ordinary
shares. We are not selling any of our ordinary shares under this prospectus and will not receive any of the proceeds from the sale of
the Shares by the Selling Shareholders. We will, however, receive the net proceeds of any Warrants exercised for cash.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">You should rely only on the information contained in this prospectus. We
have not, and the Selling Shareholders have not, authorized anyone to provide you with information other than the information that has
been provided or incorporated by reference in this prospectus and your reliance on any unauthorized information or representation is at
your own risk. The information appearing in this prospectus, the documents incorporated by reference in this prospectus and any free writing
prospectus authorized for use in connection with this offering is accurate only as of its respective date, regardless of the time of delivery
of the respective document or of any sale of securities covered by this prospectus. Our business, financial condition, results of operations
and prospects may have changed since those dates.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">To the extent there is a conflict between the information contained in
this prospectus, on the one hand, and the information contained in any document incorporated by reference that was filed with the SEC
before the date of this prospectus, on the other hand, you should rely on the information in this prospectus. If any statement in a document
incorporated by reference is inconsistent with a statement in another document incorporated by reference having a later date, the statement
in the document having the later date modifies or supersedes the earlier statement. These documents contain important information you
should consider when making your investment decision.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: red">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This prospectus does not constitute an offer to sell or the solicitation
of an offer to buy any of our securities other than the securities covered hereby, nor does this prospectus constitute an offer to sell
or the solicitation of an offer to buy any securities of the Company in any jurisdiction to any person to whom it is unlawful to make
such offer or solicitation in such jurisdiction. You should read this prospectus, including any information incorporated by reference,
and any free writing prospectus authorized for use in connection with this offering, in its entirety before making an investment decision.
You should also read and consider the information in the documents to which we have referred you in the sections entitled &ldquo;Where
You Can Find More Information&rdquo; and &ldquo;Incorporation of Certain Information by Reference.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In this prospectus, unless the context indicates otherwise the terms &ldquo;Portage
Biotech Inc.,&rdquo; &ldquo;the Company,&rdquo; &ldquo;our Company,&rdquo; &ldquo;Portage,&rdquo; &ldquo;we,&rdquo; &ldquo;us&rdquo; or
&ldquo;our&rdquo; are used interchangeably and mean Portage Biotech Inc. and its subsidiaries.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This prospectus contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as &ldquo;believe,&rdquo;
&ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;intend,&rdquo; &ldquo;estimate,&rdquo; &ldquo;will,&rdquo; &ldquo;should,&rdquo;
&ldquo;could,&rdquo; &ldquo;would,&rdquo; &ldquo;may,&rdquo; &ldquo;target,&rdquo; &ldquo;project,&rdquo; &ldquo;predict,&rdquo; &ldquo;plan,&rdquo;
&ldquo;potential,&rdquo; &ldquo;continue,&rdquo; &ldquo;indicate,&rdquo; &ldquo;suggests,&rdquo; &ldquo;may,&rdquo; &ldquo;designed to,&rdquo;
&ldquo;ongoing,&rdquo; &ldquo;forecast,&rdquo; and similar references, although not all forward-looking statements contain these words.
Forward-looking statements are neither historical facts nor assurances of future performance. These statements are based only on our current
beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events
and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent
uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. We have
made the decision to discontinue our sponsored trial for the invariant natural killer T-cell (&ldquo;<B>iNKT</B>&rdquo;) program and pause
further patient accrual to our sponsored adenosine program for both PORT-6 and PORT-7. In the event that we resume these clinical trials
and further development of our programs, our risks and uncertainties include, but are not limited to:</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&#8239;&nbsp;</P>


<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our plans and ability to develop and commercialize product candidates and the timing of these development programs;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>clinical development of our product candidates, including the timing for availability and release of results of current and future
clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our expectations regarding regulatory communications, submissions or approvals;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>the potential functionality, capabilities, benefits and risks of our product candidates as compared to others;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our maintenance and establishment of intellectual property rights in our product candidates;</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                                                                                         <TR STYLE="vertical-align: top">
<TD><P STYLE="margin-top: 0; margin-bottom: 0"></P>
    <P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our need for financing and our estimates regarding our capital requirements and future revenues
and profitability;</TD></TR>
                                                                                                                                                                                                                         </TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our estimates of the size of the potential markets for our product candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD><P STYLE="margin-top: 0; margin-bottom: 0">our
selection and licensing of product candidates; and&nbsp;</P></TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                      <TR STYLE="vertical-align: top">
<TD><FONT STYLE="font-family: Symbol">&nbsp;</FONT></TD><TD><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD>our ability to maintain the listing of our ordinary shares on <FONT STYLE="color: #212529; background-color: white">The
Nasdaq Stock Market LLC (&ldquo;</FONT><B>Nasdaq</B>&rdquo;).</TD></TR>
                                                                                                                                                                               </TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The risks and uncertainties set forth above are not exhaustive and additional
factors, including those identified in this prospectus under the heading &ldquo;Risk Factors,&rdquo; and factors described elsewhere in
this prospectus and in other filings we periodically make with the SEC, including the&nbsp;other risks and uncertainties identified in
Item 3.D. Risk Factors in our Annual Report on Form 20-F for the year ended March 31, 2024, could adversely affect our business and financial
performance. Therefore, you should not rely unduly on any of these forward-looking statements. Forward-looking statements contained in
this prospectus speak as of the date hereof and we do not undertake any obligation to update or revise any of these forward-looking statements,
whether as a result of new information, future events and developments or otherwise, except as required by law.&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<DIV STYLE="padding: 10pt; border: Black 1pt solid">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>PROSPECTUS SUMMARY</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>The following summary highlights certain information contained
elsewhere or incorporated by reference in this prospectus. This summary provides an overview of selected information and does not
contain all of the information you should consider in making your investment decision. Therefore, you should read the entire
prospectus and the documents incorporated by reference herein carefully before investing in our securities. Investors should
carefully consider the information set forth under &ldquo;Risk Factors&rdquo; beginning on page 9 of this prospectus and the
financial statements and other information incorporated by reference in this prospectus.</I><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Overview</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Due to our future funding needs for clinical development of our programs
as well as the current capital raising market for biotechnology companies, we made the decision to discontinue the IMPORT-201 trial (PORT-2)
for our iNKT program and to pause further patient accrual to the ADPORT-601 trial (PORT-6 and PORT-7) for our adenosine program. The
PORT-3 investigator trial is continuing, and all existing patients in the ADPORT-601 study will continue until disease progression. We
are continuing to collect and analyze data from these patients. We plan to replace a patient who withdrew and is unevaluable for the
28-day dose limiting toxicity period. We are exploring strategic alternatives, which may include finding a partner for one or more of
our assets, a sale of our company, a merger, restructurings, both in and out of court, company wind down, further financing efforts or
other strategic action. The following discussion reflects our operations in the event we were to raise additional capital to fund the
clinical development of our programs.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">We are a clinical stage immune-oncology company advancing
treatments we believe will be first-in-class therapies that target known checkpoint resistance pathways to improve long-term treatment
response and quality of life in patients with invasive cancers.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Our access to next-generation technologies provides
the capability to identify and understand biological mechanisms, clinical therapies and product development strategies that could accelerate
these programs through the translational pipeline.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">We source and develop early- to mid-stage treatments
that we believe will be first-in-class therapies for a variety of cancers, by funding, implementing viable, cost-effective product development
strategies, clinical counsel/trial design, shared services, financial and project management to enable efficient, turnkey execution of
commercially informed development plans. Our drug development pipeline portfolio encompasses product candidates or technologies based
on biology addressing known resistance pathways/mechanisms of current checkpoint inhibitors with established scientific rationales.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>The Portage Approach</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Our <FONT STYLE="background-color: white">mission has been to advance and grow a
portfolio of innovative, early-stage oncology assets based on the latest scientific breakthroughs focused on overcoming immune resistance
and expanding the addressable patient population. Given these foundations, we have managed capital allocation and risk as much as we have
overseen drug development. By focusing our efforts on translational medicine and pipeline diversification, we have sought to mitigate
overall exposure to many of the inherent risks of drug development.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our approach has been guided by the following core elements:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Portfolio diversification to mitigate risk and maximize optionality;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Capital allocation based on risk-adjusted potential, including staged funding to pre-specified scientific
and clinical results;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Virtual infrastructure and key external relationships to maintain a lean operating base;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Internal development capabilities complemented by external business development;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Rigorous asset selection for broad targets with disciplined ongoing evaluation;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Focus on translational medicine and therapeutic candidates with single agent activity;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Conduct randomized trials early and test non-overlapping mechanisms of action; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Improve potential outcomes for patients with invasive cancers.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">We have executed such approach through our internal core team and our network
of experts, contract labs and academic partners.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Our Science Strategy</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><FONT STYLE="color: #212529; background-color: white">Prior to our decision
to discontinue our iNKT IMPORT-201 sponsored study and pause further patient accrual </FONT><FONT STYLE="color: #212529">to the ADPORT-601
trial <FONT STYLE="background-color: white">for our adenosine program, our goal has been to develop immuno-oncology therapeutics that
will dramatically improve the standard-of-care for patients with cancer. The key elements of our scientific strategy have been to</FONT></FONT>:</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Build a pipeline of differentiated oncology therapeutic candidates that are diversified by mechanism,
broad targets, therapeutic approach, modality, stage of development, leading to a variety of deal types that can be executed with partners;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

</DIV>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<DIV STYLE="padding: 10pt; border: Black 1pt solid">

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Expand our pipeline through research collaborations, business development and internally designed programs;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Continue to advance and evolve our pipeline; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Evaluate strategic opportunities to accelerate development timelines and maximize the value of our portfolio.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white"><B>Our Pipeline</B></P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">We have built a pipeline of immuno-oncology
therapeutic candidates and programs that are diversified by mechanism, therapeutic approach, modality and stage of development. Prior
to our decision to discontinue further development of our iNKT program and pause further patient accrual to our adenosine program, we
rigorously assessed each of our programs on an ongoing basis using internally defined success criteria to justify continued investment
and determine proper capital allocation. When certain programs do not meet our de-risking criteria for advancement, we look to monetize
or terminate those programs and preserve our capital and resources to invest in programs with greater potential.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; background-color: white">

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">The charts below set forth, as
of August 14, 2024, the state of our immuno-oncology therapeutic product candidates and programs before development activities were discontinued
and/or paused except for PORT-3, which is being evaluated as part of an investigator sponsored study without funding from us.&nbsp; Additionally,
notwithstanding our decision to pause further development, PORT-7 remains in Phase 1a from an IND perspective, though we have not commenced
dosing patients. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information,
future events or otherwise.&nbsp; Before you make an investment decision regarding us, you should make your own analysis of forward-looking
statements and our projections about candidate and program development and results.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt; text-align: center">&nbsp;<IMG SRC="pipe.jpg" ALT=""></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red">&nbsp;</P>

</DIV>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red">&nbsp;</P>

<DIV STYLE="padding: 10pt; border: Black 1pt solid">

<P STYLE="margin: 0pt 0; font-size: 10pt; color: Red">&nbsp;</P>

<P STYLE="text-align: center; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"><IMG SRC="pipe2.jpg" ALT=""></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Recent Developments</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529"><I>1-for-20 Reverse Stock Split</I></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Our board of directors approved the Reverse Split of
our ordinary shares at a ratio of 1-for-20. Beginning with the opening of trading on August 15, 2024, our ordinary shares began trading
on the Nasdaq Capital Market on a split-adjusted basis under the existing trading symbol &ldquo;PRTG&rdquo;.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">The Reverse Split was implemented to increase the per
share trading price of our ordinary shares for the purpose of ensuring a share price high enough to comply with the minimum $1.00 bid
price requirement for continued listing on the Nasdaq Capital Market.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">As a result of the Reverse Split, every twenty (20) pre-split ordinary
shares were converted into one (1) post-split ordinary share. Any fractional shares resulting from the Reverse Split were rounded up
to the nearest whole post-split ordinary share. The Reverse Split affected all shareholders uniformly and did not alter any shareholder&rsquo;s
percentage interest in our ordinary shares, except for adjustments that may have resulted from the treatment of fractional shares. All
outstanding options and warrants entitling their holders to purchase our ordinary shares were adjusted as a result of the Reverse Split,
in accordance with the terms of each such security. In addition, the number of ordinary shares reserved for future issuance pursuant
to our equity incentive plans were also appropriately adjusted. The number of authorized ordinary shares was not proportionately reduced
because we have an unlimited number of authorized ordinary shares available for issuance, as permitted under the laws of the British
Virgin Islands (the &ldquo;<B>BVI</B>&rdquo;).</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

</DIV>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<DIV STYLE="border: Black 1pt solid; padding: 10pt">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Additional Background</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">On October 3, 2023, we issued and sold, pursuant to the Securities Purchase
Agreement, in a registered direct offering (the &ldquo;<B>Registered Direct Offering</B>&rdquo;) by us directly to a certain Selling Shareholder,
(i) 98,500 of our ordinary shares at a purchase price of $38.00 per share and (ii) pre-funded warrants (the &ldquo;<B>Pre-Funded Warrants</B>&rdquo;)
to purchase up to 59,395 ordinary shares, at a purchase price of $37.98 per Pre-Funded Warrant (the &ldquo;<B>Pre-Funded Warrant Shares</B>&rdquo;),
for aggregate net proceeds of approximately $5.3 million after deducting the placement agent&rsquo;s fees and related offering expenses.
These securities were offered by us pursuant to an effective shelf registration statement on Form F-3 (File No. 333-253468) previously
filed with the SEC on February 24, 2021 and declared effective by the SEC on March 8, 2021.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Also pursuant to the Securities Purchase Agreement, for each ordinary share
and Pre-Funded Warrant issued and sold in the Registered Direct Offering, an accompanying Series A Warrant, Series B Warrant and Series
C Warrant was issued and sold to such Selling Shareholder in the concurrent Private Placement. Each Series A Warrant is exercisable for
one Series A Warrant Share at an exercise price of $38.00 per share, is immediately exercisable and will expire 18 months from the date
of issuance. Each Series B Warrant is exercisable for one Series B Warrant Share at an exercise price of $45.20 per share, is immediately
exercisable and will expire three years from the date of issuance. Each Series C Warrant is exercisable for one Series C Warrant Share
at an exercise price of $45.20 per share, is immediately exercisable and will expire five years from the date of issuance.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Pursuant to an engagement letter, dated as of August 26, 2023, between
us and H.C. Wainwright &amp; Co., LLC (the &ldquo;<B>Placement Agent</B>&rdquo;), we issued to designees of the Placement Agent warrants
to purchase up to 7,896 Placement Agent Warrant Shares, which represented 5.0% of the aggregate number of ordinary shares and Pre-Funded
Warrants sold in the Registered Direct Offering. The Placement Agent Warrants have an exercise price equal to $47.50, or 125% of the offering
price per share sold in the Registered Direct Offering, and will expire five years from the commencement of the sales pursuant to the
Registered Direct Offering and Private Placement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The Warrants were offered and sold without registration under the Securities
Act in reliance on the exemption provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated thereunder.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Corporate Information</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">We were originally incorporated in Ontario, Canada in 1973. We were inactive
until 1985. Then, between 1986 and 2012, we were engaged in variety of businesses. Between 1986 to 2012, we went through several name
changes ending with &ldquo;Bontan Corporation Inc.&rdquo; In December 2012, we decided to change the focus of our business activities
and, in 2013, we began our business focus within the biotechnology sector. On June 4, 2013, we acquired Portage Pharma Ltd., a biotech
private limited company formed under the laws of the BVI, by an exchange of shares. On July 5, 2013, we changed our name to &ldquo;Portage
Biotech Inc.&rdquo; and moved our jurisdiction from Ontario, Canada, to the BVI under a certificate of continuance issued by the Registrar
of Corporate Affairs of the BVI.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><BR STYLE="clear: both"></P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<DIV STYLE="padding: 10pt; border: Black 1pt solid">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">We are a BVI business company incorporated under the BVI Business Companies
Act (Revised Edition 2020, as amended) (the &ldquo;<B>BVI Act</B>&rdquo;) with our registered office located at Clarence Thomas Building,
P.O. Box 4649, Road Town, Tortola, British Virgin Islands, VG1110. Our U.S. agent, Portage Development Services, Inc., is located at 59
Wilton Road, Westport, CT 06880. Our telephone number is (203) 221-7378. Our website address is https://www.portagebiotech.com. The inclusion
of our website address is intended to be an inactive textual reference only and not an active hyperlink to our website. The information
contained in, or that can be accessed through, our website address is not incorporated by reference in this prospectus and is not part
of this prospectus. The SEC also maintains an internet website located at www.sec.gov that contains the information we file or furnish
electronically with the SEC.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

</DIV>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<DIV STYLE="border: Black 1pt solid; padding: 10pt">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>THE OFFERING</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 35%"><FONT STYLE="font-size: 10pt">Ordinary shares offered by the Selling Shareholders:</FONT></TD>
    <TD STYLE="width: 65%"><FONT STYLE="font-size: 10pt">Up to 481,581 Shares following issuance upon exercise of the Warrants.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Ordinary shares outstanding prior this offering:</FONT></TD>
    <TD>1,048,615<SUP>1</SUP> ordinary shares assuming no exercise of the Series A Warrants, Series
B Warrants or Series C Warrants issued in the Private Placement and no exercise of the Placement Agent Warrants issued to the Placement
Agent.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Ordinary shares outstanding after this offering:</FONT></TD>
    <TD>1,530,196<SUP>1</SUP> ordinary shares assuming full exercise of all the Series A Warrants, Series
B Warrants and Series C Warrants issued in the Private Placement and full exercise of all the Placement Agent Warrants issued to the Placement
Agent.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Use of proceeds:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">We will not receive any proceeds from the sale of the Shares offered hereby by the Selling Shareholders, although we will receive the net proceeds of any Warrants exercised for cash. See the section entitled &ldquo;Use of Proceeds&rdquo; for more information.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Risk factors:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">You should read the &ldquo;Risk Factors&rdquo; section of this prospectus for a discussion of factors to consider carefully before deciding to invest in these securities.</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Nasdaq Capital Market symbol:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">&ldquo;PRTG&rdquo;</FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><SUP>1 </SUP>The number of ordinary shares to be outstanding after this offering is based on 989,220 ordinary
shares outstanding as of March 31, 2024, plus 59,395 ordinary shares issued upon the exercise of pre-funded warrants on May 29, 2024 that
were issued in the Registered Direct Offering and excludes:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Restricted stock units with respect to 18,467 ordinary shares outstanding as of March 31, 2024, which vested
immediately on the date of grant and are subject to certain restrictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"><P STYLE="margin: 0pt 0; font-size: 10pt">90,281 ordinary shares issuable upon the exercise of options outstanding as of March 31, 2024
at a weighted-average exercise price of $203.61 per share; and</P></TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">34,832 ordinary shares available for future issuance under our Amended and Restated 2021 Equity
Incentive Plan as of March 31, 2024.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Unless otherwise indicated, all information in this prospectus assumes full exercise of all the Series
A Warrants, Series B Warrants and Series C Warrants issued the Private Placement and full exercise of all the Placement Agent Warrants
issued to the designees of the Placement Agent as compensation in connection with the Registered Direct Offering and the Private Placement.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</DIV>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>RISK FACTORS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Investing in our securities involves a high degree of risk. Before investing
in our securities, you should carefully consider the risks, uncertainties and assumptions described below, in the section under the heading
&ldquo;Risk Factors&rdquo; included in our Annual Report on Form 20-F for our most recent fiscal year, our Reports of Foreign Private
Issuer on Form 6-K, <FONT STYLE="background-color: white">any amendments or updates thereto reflected in subsequent filings with the SEC,
and in other reports we file with the SEC that are incorporated by reference herein. </FONT>Our business, financial condition, results
of operations and future growth prospects could be materially and adversely affected by any of these risks. In these circumstances, the
market price of our ordinary shares could decline, and you may lose all or part of your investment. </I></P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I></I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: #212529"><FONT STYLE="background-color: white"><B>The following
is a brief discussion of the most significant risk factors that are specific to our operations and industry and that may have a material
impact on, or constitute the most significant risk factors in respect of, our future financial performance in the event that we were to
raise additional capital to fund the clinical development of our programs.</B></FONT></P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><U>Risks Related to this Offering</U></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>


<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We have current and future capital needs, and, if we decide to resume
enrollment in our clinical trials, there are uncertainties as to our ability to raise additional funding. </I></B></P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B><I>&nbsp;</I></B><P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: #212529"><FONT STYLE="background-color: white">Our current cash
resources will not cover all of our operational costs and the needs of our subsidiaries to progress towards clinical trials, if we decide
to resume enrollment in our clinical programs. Additional capital would be needed to test product candidate in human trials, obtain
regulatory approvals and ultimately to commercialize such product candidates if approved.</FONT></P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In addition, our future cash requirements may vary materially from those
now expected. For example, our future capital requirements may increase if:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we experience scientific progress sooner than expected in our future discovery, research and development
projects, if we expand the magnitude and scope of these activities, or if we modify our focus as a result of our discoveries;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we experience setbacks in our progress with pre-clinical studies and clinical trials are delayed;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we experience delays or unexpected increased costs in connection with obtaining regulatory approvals,
particularly in light of the current inflationary environment;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we are required to perform additional pre-clinical studies and/or clinical trials;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we experience unexpected or increased costs relating to preparing, filing, prosecuting, maintaining, defending
and enforcing patent claims; or</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we elect to develop, acquire or license new technologies and products.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: #212529"><FONT STYLE="background-color: white">We have incurred,
and, if we decide to resume enrollment in our clinical programs, we expect to continue to incur substantial costs related to the development
of our product candidates, including costs related to the clinical trials for our adenosine platform. If sufficient capital is not available
and we decide to resume enrollment in our clinical programs, we may be required to delay, reduce the scope of, eliminate or divest of
one or more of our research or development projects, any of which could have a material adverse effect on our business, financial condition,
prospects or results of operations</FONT></P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Furthermore, under General Instruction I.B.5 to Form F-3 (the &ldquo;<B>Baby
Shelf Rule</B>&rdquo;), the amount of funds we can raise through primary public offerings of securities in any 12-month period using a
registration statement on Form F-3 is limited to one-third of the aggregate market value of the ordinary shares held by our non-affiliates,
which limitation may change over time based on our stock price, number of ordinary shares outstanding and the percentage of ordinary shares
held by non-affiliates. We therefore are limited by the Baby Shelf Rule as of the filing of this post-effective amendment, until such
time as our non-affiliate public float exceeds $75 million.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Our need for future financing may result in the issuance of additional
securities which may cause our shareholders to experience dilution.</I></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B><I>&nbsp;</I></B><P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our cash requirements may vary from those now planned depending upon numerous
factors, including the results of potential future research and development activities. We expect our expenses to increase if and when
we initiate and conduct additional clinical trials, and seek marketing approval for our product candidates. Accordingly, we will need
to obtain substantial additional funding in connection with our continuing operations. Our securities may be offered to investors at a
price lower than the price per share paid by existing shareholders, or upon terms which may be deemed more favorable than those of existing
shareholders. In addition, the issuance of securities in any future financing may dilute the equity ownership of existing shareholders
and may have the effect of depressing the market price for our securities, including the ordinary shares. Moreover, we may issue derivative
securities, including options and/or warrants, from time to time, which may further dilute the equity ownership of our shareholders. No
assurance can be given as to our ability to procure additional financing, if required, and on terms deemed favorable to us. To the extent
additional capital is required and cannot be raised successfully, we may then have to limit our then current operations and/or may have
to curtail certain, if not all, of our business objectives and plans.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>



<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B><I>We have a history of operating losses and may never achieve
profitability in the future.</I></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Historically, we have generated only a limited amount of business income,
notwithstanding a highly valued asset distribution to our shareholders of share ownership of Biohaven Pharmaceuticals Holding Company
Ltd. (&ldquo;<B>Biohaven</B>&rdquo;).</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: #212529"><FONT STYLE="background-color: white">Prior to our decision
to discontinue our iNKT program and pause further patient accrual in our adenosine program, our objective was to enable research and development
so as to create early- to mid-stage, first- and best-in-class therapies for a variety of cancers, by providing funding, strategic business
and clinical counsel, and shared services, with the goal of creating viable products that may be monetized through licensing, manufacturing
and distribution or outright sale. Our principal activities were engaging in research and development to identify and validate new drug
targets that could become marketed drugs in the future. If we decide to resume enrollment in our clinical programs, we will require significant
financial resources without any income, and we expect to continue incurring operating losses for the foreseeable future.</FONT></P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our ability to generate revenue in the future or achieve profitable operations
is largely dependent upon our ability to attract and maintain experienced management and know-how to develop new drug candidates and to
partner with major pharmaceutical companies to successfully commercialize any successful drug candidates. It takes many years and significant
financial resources to successfully develop pre-clinical or early clinical drug candidates into marketable drugs, and we cannot assure
you that we will be able to achieve these objectives. Although, we were successful in achieving significant value growth in an investment
made in Biohaven, which resulted in the distribution of Biohaven shares as an asset dividend to our shareholders with a then market value
of approximately $153 million in fiscal 2018, we cannot guarantee that we will be able to achieve any similar success in our future business
activities.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>Our share price has fluctuated in the past, has recently been volatile
and may be volatile in the future, and as a result, investors in our ordinary shares could incur substantial losses.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our share price has fluctuated in the past, has recently been volatile,
and may be volatile in the future. The stock market in general and the market for biotechnology companies in particular has experienced
volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, investors
may experience losses on their investment in our ordinary shares. The market price for our ordinary shares may be influenced by many factors,
including, but not limited to, the following:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">investor reaction to our business strategy;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our ability or inability to raise additional capital and the terms on which we raise it;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the success of competitive products or technologies;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">results of clinical trials or future product candidates or those of our competitors;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">regulatory or legal developments, especially changes in laws or regulations applicable to our product
candidates;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">introductions and announcements of new product candidates by us, results of clinical trials, our commercialization
partners, or our competitors, and the timing of these introductions or announcements;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">actions taken by regulatory agencies with respect to our clinical studies, manufacturing process or sales
and marketing terms;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">variations in our financial results or those of companies that are perceived to be similar to us;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the success of our efforts to acquire or in-license additional products or product candidates;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developments concerning our collaborations;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures
or capital commitments;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">developments or disputes concerning patents or other proprietary rights, including patents, litigation
matters and our ability to obtain patent protection for our products;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the recruitment or departure of key personnel;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">market conditions in the pharmaceutical and biotechnology sectors;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">declines in the market prices of publicly traded stocks generally;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">actual or anticipated changes in earnings estimates or changes in stock market analyst recommendations
regarding our ordinary shares, other comparable companies, or our industry generally;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">trading volume of our ordinary shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">sales of our ordinary shares by us or our shareholders;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">general economic, industry and market conditions;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">other events or factors, including those resulting from such events, or the prospect of such events, including
war, terrorism and other international conflicts, public health issues including health epidemics or pandemics such as COVID-19, and natural
disasters such as fire, hurricanes, earthquakes, tornados or other adverse weather and climate conditions, whether occurring in the United
States or elsewhere, could disrupt our operations, disrupt the operations of our suppliers or result in political or economic instability;
and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the other risks described in this &ldquo;Risk Factors&rdquo; section and the &ldquo;Risk Factors&rdquo;
sections included in the documents incorporated by reference in this prospectus.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><I>We have additional ordinary shares available for issuance, which,
if issued, could adversely affect the rights of the holders of our ordinary shares.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our Memorandum and Articles of Association (as amended from time to time,
&ldquo;<B>Memorandum and Articles</B>&rdquo;) authorize the issuance of an unlimited number of ordinary shares, upon resolution of our
board of directors, without shareholder approval. Any future issuances of ordinary shares would further dilute the percentage ownership
of us held by holders of our ordinary shares. In addition, the issuance of additional ordinary shares may be used as an &ldquo;anti-takeover&rdquo;
device without further action on the part of our shareholders, and may adversely affect the holders of our ordinary shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B><I>We may lose our foreign private issuer status, which would then require us to comply with
the Exchange Act&rsquo;s and Nasdaq&rsquo;s domestic reporting regime and cause us to incur significant legal, accounting and other expenses.
</I></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: #212529"><FONT STYLE="background-color: white">We are a foreign
private issuer. In order to maintain our current status as a foreign private issuer, at least 50% of our outstanding ordinary shares must
continue to be either directly or indirectly owned of record by non-residents of the United States. If more than 50% of our outstanding
ordinary shares are instead held by U.S. residents, then in order to continue to maintain our foreign private issuer status, (i) a majority
of our executive officers or directors must not be U.S. citizens or residents, (ii) more than 50% of our assets must not be located in
the United States, and (iii) our business must be administered principally outside the United States.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; color: #212529"><FONT STYLE="background-color: white">Losing our status
as a foreign private issuer would require us to comply with all of the periodic disclosure and current reporting requirements of the Securities
Exchange Act of 1934, as amended (the &ldquo;<B>Exchange Act</B>&rdquo;) applicable to U.S. domestic issuers. We also will be required
to make changes in our corporate governance practices in accordance with various SEC and Nasdaq rules. The regulatory and compliance costs
to us under U.S. securities laws, if we are required to comply with the reporting requirements applicable to a U.S. domestic issuer, would
be significantly higher than the cost we would incur as a foreign private issuer. As a result, we would expect that a loss of foreign
private issuer status will increase our legal and financial compliance costs and will make some activities highly time consuming and costly.
We also expect that if we will be required to comply with the rules and regulations applicable to U.S. domestic issuers, it will make
it more difficult and expensive for us to obtain director and officer liability insurance; we may therefore be required to accept reduced
coverage or incur substantially higher costs to obtain coverage. These rules and regulations could also make it more difficult for us
to attract and retain qualified members of our board of directors.</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In accordance with Nasdaq Listing Rule 5615(a)(3), <FONT STYLE="color: #212529; background-color: white">we
comply with home country governance requirements and certain exemptions thereunder rather than complying with certain of the corporate
governance requirements of Nasdaq which may afford less protection to our shareholders than they would otherwise have if we complied fully
with Nasdaq&rsquo;s corporate governance requirements.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">BVI law does not require that a majority of our board
of directors consist of independent directors or that our board committees consist of entirely independent directors. Our board of directors
and board committees, therefore, may include fewer independent directors than would be required if we were subject to Nasdaq Listing Rule
5605(b)(1). In addition, we will not be subject to Nasdaq Listing Rule 5605(b)(2), which requires that independent directors must regularly
have scheduled meetings at which only independent directors are present.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">We also are exempt from the Nasdaq listing rules as
to quorum, and instead follow the quorum rules for shareholder meetings under BVI law. We also are exempt from the Nasdaq listing rules
so as to not be required to obtain shareholder approval for certain issuance of securities, shareholder approval of share option plans
and change of control transactions under Nasdaq Listing Rule 5635 and to hold annual shareholder meetings under Nasdaq Listing Rule 5620(a).</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The determination of foreign private issuer status is made annually on
the last business day of an issuer&rsquo;s most recently completed second fiscal quarter. As of September 30, 2023, we satisfied the requirements
for retaining our foreign private issuer status as such date. Although we satisfied the foreign private issuer status as of September
30, 2023, we are uncertain on whether we will satisfy the foreign private issuer requirements on the determination date as of September
30, 2024. Assuming we did not satisfy the requirements to remain a foreign private issuer as of September 30, 2024, we would cease to
be a foreign private issuer and cease to be eligible for the foregoing exemptions and privileges effective April 1, 2025.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B><U>Risks Related to Ownership of our Shares </U></B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><FONT STYLE="background-color: white"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><FONT STYLE="background-color: white"><B><I>We may not be able to regain, or maintain, compliance
with the continued listing requirements of The Nasdaq Capital Market</I></B></FONT><B><I>.</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->



<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">Our ordinary shares are listed on the Nasdaq Capital
Market, and we are therefore subject to its continued listing requirements, including requirements with respect to the market value of
our publicly-held shares, market value of our listed shares, minimum bid price per share, and minimum shareholders&rsquo; equity, among
others. If we fail to satisfy one or more of the requirements, we may be delisted from the Nasdaq Capital Market.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">On March 7, 2024, we received notice (the &ldquo;<B>Notice</B>&rdquo;)
from Nasdaq that we are not currently in compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital
Market, as set forth in Nasdaq Listing Rule 5550(a)(2). The Notice indicated that, consistent with Nasdaq Listing Rule 5810(c)(3)(A),
we have 180 calendar days, or until September 3, 2024, to regain compliance with the minimum bid price requirement by having the closing
bid price of our ordinary shares meet or exceed $1.00 per share for at least ten consecutive business days. The notification had no immediate
effect on the listing of our ordinary shares, and our ordinary shares will continue to trade on the Nasdaq Capital Market under the symbol
&ldquo;PRTG&rdquo; at this time. We effected the Reverse Split with the purpose of ensuring a share price high enough to regain compliance
with the minimum bid price requirement.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">If we do not regain compliance by September 3, 2024,
we may be eligible for an additional 180 calendar day grace period. If we fail to regain compliance during the applicable period, we will
receive notification from Nasdaq that our ordinary shares are subject to delisting. Such notification will have no immediate effect on
our listing on the Nasdaq Capital Market, nor will it have an immediate effect on the trading of our ordinary shares pending such hearing.
At that time, we may then appeal the delisting determination to a Nasdaq hearings panel. There can be no assurance, however, that we will
be able to regain compliance with Nasdaq&rsquo;s minimum bid price requirement. If we regain compliance with Nasdaq&rsquo;s minimum bid
price requirement, there can be no assurance that we will be able to maintain compliance with the continued listing requirements for the
Nasdaq Capital Market or that our ordinary shares will not be delisted from the Nasdaq Capital Market in the future. In addition, we may
be unable to meet other applicable listing requirements of the Nasdaq Capital Market, including maintaining minimum levels of shareholders&rsquo;
equity or market values of our ordinary shares in which case, our ordinary shares could be delisted notwithstanding our ability to demonstrate
compliance with the minimum bid price requirement.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">Additionally, Nasdaq Listing Rule 5550(b)(1) requires
companies listed on the Nasdaq Capital Market to maintain shareholders&rsquo; equity of at least $2.5 million for continued listing. As
of March 31, 2024, our shareholders&rsquo; equity was $3.3 million and there can be no assurance that we will be able to maintain or increase
our shareholders&rsquo; equity in the future. If our shareholders&rsquo; equity falls below $2.5 million, as a result of operating losses
or for other reasons, or if we are unable to demonstrate to Nasdaq&rsquo;s satisfaction that we subsequently regained compliance with
this requirement, Nasdaq will notify us of such non-compliance. If we receive such notice from Nasdaq, in accordance with the Nasdaq Listing
Rules, we will have 45 calendar days from the date of the notification to submit a plan to regain compliance with Nasdaq Listing Rule
5550(b)(1). If our compliance plan is accepted, we may be granted up to 180 calendar days from the date of the initial notification to
evidence compliance. If our compliance plan is not accepted or we are otherwise unable to evidence compliance within Nasdaq&rsquo;s allotted
timeframe, Nasdaq may take steps to delist our ordinary shares.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529"><FONT STYLE="background-color: white">Additionally,
Nasdaq may take the position that we are a &ldquo;public shell&rdquo; under Nasdaq rules, which could have negative consequences, including
the potential delisting of our ordinary shares from the Nasdaq Capital Market. We have no current plans to delist our ordinary shares
from Nasdaq. However, following the decision to discontinue our sponsored clinical trial for the INKT program and pause further patient
accrual to our sponsored adenosine program, we may be treated as a public shell under Nasdaq rules. Although Nasdaq evaluates whether
a listed company is a public shell company based on a facts and circumstances determination, a Nasdaq-listed company with no or nominal
operations and either no or nominal assets, assets consisting solely of cash and cash equivalents, or assets consisting of any amount
of cash and cash equivalents and nominal other assets is generally considered to be a public shell company.</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">Delisting from the Nasdaq Capital Market may adversely
affect our ability to raise additional financing through the public or private sale of equity securities, may significantly affect the
ability of investors to trade our securities and may negatively affect the value and liquidity of our ordinary shares. Delisting also
could have other negative results, including the potential loss of employee confidence, the loss of institutional investors or interest
in business development opportunities.</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0; background-color: white; color: #212529">If we are delisted from Nasdaq and we are not able
to list our ordinary shares on another exchange, our ordinary shares could be quoted on the Over-The-Counter Bulletin Board or in the
&ldquo;pink sheets.&rdquo; As a result, we could face significant adverse consequences including, among others:</P>

<P STYLE="font-size: 10pt; text-indent: 23.05pt; margin: 0pt 0; background-color: white; color: #212529">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a limited availability of market quotations for our securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a determination that our shares are a &ldquo;penny stock&rdquo; which will require brokers trading in
our ordinary shares to adhere to more stringent rules and possibly result in a reduced level of trading activity in the secondary trading
market for our securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a limited amount of news and little or no analyst coverage for us;</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">we would no longer qualify for exemptions from state securities registration requirements, which may require
us to comply with applicable state securities laws; and</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a decreased ability to issue additional securities (including pursuant to short-form Registration Statements
on Form F-3) due to the Baby Shelf Rule or obtain additional financing in the future.</TD></TR></TABLE>

<P STYLE="margin: 0pt; text-align: left; font-size: 10pt; text-indent: 0pt; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt; text-align: left; font-size: 10pt; text-indent: 0pt; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-indent: 23.05pt; background-color: white; color: #212529">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>USE OF PROCEEDS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The net proceeds from any disposition of Shares covered by this prospectus
will be received by the Selling Shareholders. We will not receive any of the proceeds from any such ordinary shares offered by this prospectus.
We will, however, receive the net proceeds of any Warrants exercised for cash. We intend to use any such net proceeds to extend the cash
runway needed to complete any of the potential strategies being considered including, resuming our clinical trials and further development
of our programs, and for general working capital purposes.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>DIVIDEND POLICY</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We do not plan on declaring any cash dividends on our ordinary shares in
the foreseeable future. We expect to retain all available cash funds and future earnings, if any, to fund the development and growth of
our business. Any future determination to pay dividends, if any, on our ordinary shares will be at the discretion of our board of directors
and will depend on, among other factors, our results of operations, financial condition, capital requirements and contractual restrictions.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>SELLING SHAREHOLDERS</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B><P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Shares being offered by the Selling Shareholders consist of Shares
issuable to the Selling Shareholders upon exercise of the Warrants. We are registering the Shares in order to permit the Selling Shareholders
to offer the Shares for resale from time to time. Except for (a) the ownership of the Shares and the Warrants and (b) with respect to
the Placement Agent Warrants issued as compensation to the Placement Agent, who acted as our Placement Agent in the Registered Direct
Offering and the Private Placement, or its designees, the Selling Shareholders have not had any material relationship with us within the
past three years.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The table below lists the Selling Shareholders and other information regarding
the beneficial ownership of our ordinary shares by each of the Selling Shareholders. The second column lists the number of our ordinary
shares beneficially owned by each Selling Shareholder, based on its ownership of the Shares and Warrants, as of August 19, 2024, assuming
exercise of the Warrants held by the Selling Shareholders on that date, without regard to any limitations on exercises.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The fourth column lists the Shares being offered by the Selling Shareholders
pursuant to this prospectus.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The fifth column assumes the sale of all of the Shares offered by the Selling
Shareholders pursuant to this prospectus.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Under the terms of the Warrants, a Selling Shareholders may not exercise
the Warrants to the extent such exercise would cause such Selling Shareholder, together with its affiliates, to beneficially own a number
of ordinary shares that would exceed 4.99% of our then outstanding ordinary shares following such exercise, excluding for purposes of
such determination ordinary shares issuable upon exercise of such Warrants which have not been exercised. The number of ordinary shares
in the second and fifth columns do not reflect this limitation. The Selling Shareholders may sell all, some or none of their Shares in
this offering. See the section entitled &ldquo;Plan of Distribution&rdquo; below for further information.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Selling Shareholder</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><FONT STYLE="font-size: 10pt"><B>Number of Ordinary Shares Beneficially<BR> Owned Before this<BR> Offering<SUP>(1)</SUP></B></FONT></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;Percentage</B></P> <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>of</B></P> <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Ordinary</B></P> <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Shares</B></P> <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Beneficially Owned</B></P> <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Before this</B></P> <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Offering<SUP>(1)</SUP></B></P></TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Shares to be Sold in<BR> this Offering</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center">Number of Shares Beneficially Owned <BR>After this Offering</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="border-bottom: Black 1pt solid; font-size: 10pt; font-weight: bold; text-align: center"><P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Percentage of Total Outstanding Ordinary Shares Owned After this</B></P> <P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>Offering <SUP>(1)</SUP></B></P></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 45%; font-size: 10pt; text-align: left"><FONT STYLE="font-size: 10pt">Armistice Capital, LLC <SUP>(2)</SUP></FONT></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">473,685</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">*</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"></TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">473,685</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left"></TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Michael Mirsky<SUP>(3)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">750</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">750</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Noam Rubinstein<SUP>(3)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,737</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">1,737</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Craig Schwabe<SUP>(3)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">267</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">267</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Michael Vasinkevich<SUP>(3)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,063</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">5,063</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt"><FONT STYLE="font-size: 10pt">Charles Worthman<SUP>(3)</SUP></FONT></TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">79</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right"><FONT STYLE="font-size: 10pt">*</FONT></TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">79</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">-</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">* Represents beneficial ownership of less than one percent.</P>

<P STYLE="font-size: 10pt; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">(1) The ability to exercise the Warrants held by the Selling Shareholders is subject to a beneficial
ownership limitation that, at the time of initial issuance of the Warrants, was capped at 4.99% beneficial ownership of our issued and
outstanding ordinary shares (post-exercise). These beneficial ownership limitations may be adjusted up or down, subject to providing advanced
notice to us. Beneficial ownership as reflected in this table reflects the total number of ordinary shares potentially issuable underlying
the Warrants and does not give effect to these beneficial ownership limitations. Accordingly, actual beneficial ownership, as calculated
in accordance with Section 13(d)of the Exchange Act and Rule 13d-3 thereunder may be lower than as reflected in the table.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">(2) Consists of 473,685 ordinary shares issuable upon the exercise of the Private Warrants. The securities
are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the &ldquo;<B>Master Fund</B>&rdquo;), and
may be deemed to be beneficially owned by: (i) Armistice Capital, LLC (&ldquo;<B>Armistice Capital</B>&rdquo;), as the investment manager
of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital. The Private Warrants are subject to a beneficial
ownership limitation of 4.99%, which such limitation restricts the Selling Shareholder from exercising that portion of the Private Warrants
that would result in the Selling Shareholder and its affiliates owning, after exercise, a number of shares of common stock in excess of
the beneficial ownership limitation. The number of ordinary shares set forth in the above table does not reflect the application of this
limitation. The address of Armistice Capital Master Fund Ltd. is c/o Armistice Capital, LLC, 510 Madison Avenue, 7th Floor, New York,
NY 10022.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">(3) Each of these Selling Shareholders is affiliated with H.C. Wainwright
&amp; Co., LLC, the Placement Agent in connection with the Securities Purchase Agreement and a registered broker dealer, with a registered
address of H.C. Wainwright &amp; Co., LLC, 430 Park Ave, 3rd Floor, New York, NY 10022, and has sole voting and dispositive power over
the securities held. The number of ordinary shares beneficially owned prior to this offering consists of ordinary shares issuable upon
exercise of the Placement Agent Warrants, which were received as compensation. Each of these Selling Shareholders acquired the Placement
Agent Warrants in the ordinary course of business and, at the time the Placement Agent Warrants were acquired, each of these Selling Shareholders
had no agreement or understanding, directly or indirectly, with any person to distribute such securities. <B><BR STYLE="clear: both">
</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>CAPITALIZATION</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The following table sets forth our capitalization:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">on an actual basis as of March 31, 2024; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">on an as adjusted basis, giving effect to the issuance of an aggregate of (i) 59,395 ordinary shares
issued upon exercise of pre-funded warrants on May 29, 2024 that were issued in the Registered Direct Offering, (ii) 473,685 ordinary
shares following an assumed cash exercise of all Warrants issued in the Private Placement and (iii) 7,896 ordinary shares following an
assumed cash exercise of all Placement Agent Warrants.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The  adjusted amounts shown below are unaudited and represent management&rsquo;s
estimate. The information in this table should be read in conjunction with and is qualified by reference to the financial statements and
notes thereto and other financial information incorporated by reference into this prospectus.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">March 31, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As Adjusted</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-size: 10pt">&nbsp;</TD><TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-size: 10pt; font-weight: bold; text-align: center; border-bottom: Black 1pt solid">(U.S. Dollars in thousands)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; font-size: 10pt; text-align: left">Cash and cash equivalents</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">5,028</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">25,677</TD><TD STYLE="width: 1%; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left">Other assets:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">7,695</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">28,344</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Non-current assets</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">84</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">84</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt">Liabilities:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,879</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">2,879</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Non-current liabilities</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,571</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">1,571</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt">Equity:</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Capital stock</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">219,499</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">240,148</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Stock option reserve</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">23,841</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">23,841</TD><TD STYLE="font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left">Accumulated deficit</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(239,318</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">(239,318</TD><TD STYLE="font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="padding-left: 10pt; font-size: 10pt; text-align: left; padding-bottom: 1pt">Non-controlling interest</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(693</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">(693</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total equity</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">3,329</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">23,978</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; padding-bottom: 1pt">Total capitalization</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,145</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">11,145</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B><P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The number of ordinary shares to be outstanding after this offering is
based on 989,220 ordinary shares outstanding as of March 31, 2024, plus 59,395 ordinary shares issued upon the exercise of pre-funded
warrants on May 29, 2024 that were issued in the Registered Direct Offering and excludes:</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Restricted stock units with respect to 18,467 ordinary shares outstanding as of March 31, 2024, which vested
immediately on the date of grant and are subject to certain restrictions;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">90,281 ordinary shares issuable upon the exercise of options outstanding as of March 31, 2024 at a weighted-average exercise price of
$203.61 per share; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">34,832 ordinary shares available for future issuance under our Amended and Restated 2021 Equity Incentive
Plan as of March 31, 2024.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Unless otherwise indicated, all information in this prospectus assumes
full exercise of all the Series A Warrants, Series B Warrants and Series C Warrants issued the Private Placement and full exercise of
all the Placement Agent Warrants issued to the designees of the Placement Agent as compensation in connection with the Registered Direct
Offering and the Private Placement.</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>DESCRIPTION OF SECURITIES BEING REGISTERED</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Ordinary Shares</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The following description of our ordinary shares is only a summary. This
description is subject to, and qualified in its entirety by reference to, our Memorandum and Articles, which have previously been filed
with the SEC and in the Territory of the British Virgin Islands, pursuant to the BVI Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our authorized capital stock includes an unlimited number of ordinary shares,
with no par value per share. As of the date of this prospectus, there are (i) 1,048,777 ordinary shares issued and 1,048,615 ordinary
shares outstanding, and (ii) 162 ordinary shares held in treasury. We are not authorized to issue any preferred stock.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>Rights of Holders of Ordinary Shares</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>General.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">All of our outstanding ordinary shares are fully paid and non-assessable.
We have the right to issue ordinary shares for cash and other consideration. Additionally, ordinary shares may not be fully paid, but
are then susceptible to being forfeited by us until fully paid and non-assessable. Certificates representing our ordinary shares are issued
in registered form and book entry form. Our shareholders who are non-residents of the British Virgin Islands may freely hold and vote
their ordinary shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Dividends.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">By a resolution of directors, we may declare and pay dividends in money,
ordinary shares, or other property at such time and of such an amount as the board thinks fit if they are satisfied on reasonable grounds
that the company will, immediately after the distribution, satisfy the solvency test set forth in the BVI Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Unissued Ordinary Shares.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our unissued ordinary shares shall be at the disposal of the directors
who may without prejudice to any rights previously conferred on the holders of any existing ordinary shares or class or series of ordinary
shares offer, allot, grant options over or otherwise dispose of ordinary shares or other securities to such persons, at such times and
upon such terms and conditions as we may by resolution of the directors determine. Before issuing ordinary shares for a consideration
other than money, the directors shall pass a resolution stating the amount to be credited for the issue of the ordinary shares, and that,
in their opinion, the present cash value of the non-money consideration and money consideration for the issue is not less than the amount
to be credited for the issue of the ordinary shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Voting Rights.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Each ordinary share is entitled to one vote on all matters upon which our
ordinary shares are entitled to vote. Additionally, our directors may convene meetings of our shareholders at such times and in such-manner
and places within or outside the British Virgin Islands as the directors consider necessary or desirable. At least 10 days&rsquo; notice
of the meeting shall be given, counting from the date of service of the notice.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Upon the written request of shareholders holding 10% or more of the outstanding
voting rights attaching to our ordinary shares, the directors shall convene a meeting of shareholders not later than 45 days after deposit
of the demand. The directors shall give not less than 10 days&rsquo; notice of a meeting of shareholders to those persons whose names
at the close of business on a day to be determined by the directors appear as shareholders in our share register and are entitled to vote
at the meeting.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A meeting of shareholders is duly constituted if, at the commencement of
the meeting, there are present in person or by proxy not less than two persons. Shareholder resolutions may be decided by a show of hands
unless a poll is demanded by the chairman or one or more shareholders present in person or by proxy entitled to vote. On a show of hands,
each shareholder has one vote.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">An action that may be taken by the shareholders at a meeting may also be
taken by a resolution of shareholders consented to in writing without the need for any notice; provided, however, that where such a resolution
is passed without the written consent of a majority of the shareholders (i.e., where for example one person holding 65% of the ordinary
shares passes the resolution) a copy of such resolution shall forthwith be sent to all shareholders not consenting to such resolution.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Any shareholder that is a corporation or other entity may by resolution
of its directors or other governing body authorize a natural person to act as its representative at any meeting of our company or of any
meeting of holders of a class or series, and the person so authorized shall be entitled to exercise the same powers on behalf of the corporation
or other entity which he represents as that corporation or entity could exercise if it were an individual shareholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Transfer of Ordinary Shares.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Certificated ordinary shares in our company may be transferred by a written
instrument of transfer (which complies with the rules of the SEC and federal and state securities laws of the United States) signed by
the transferor and containing the name and address of the transferee, but in the absence of such written evidence of transfer the directors
may accept such evidence of a transfer of shares as they consider appropriate. We may also issue ordinary shares in uncertificated form.
We shall not be required to treat a transferee of a registered ordinary share in our company as a member until the transferee's name has
been entered in the share register. The register of members may be closed at such times and for such periods as the board of directors
may from time to time determine.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Liquidation.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In the case of the distribution of assets by a voluntary liquidator on
a winding-up of our company, subject to payment of, or to discharge of, all claims, debts, liabilities and obligations of our company,
any surplus assets shall then be distributed amongst our shareholders according to their rights and interests in our company according
to our Memorandum and Articles.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Calls on Ordinary Shares and Forfeiture of Ordinary Shares.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our board of directors may from time to time make calls upon shareholders
for any amounts unpaid on their ordinary shares in a notice served to such shareholders at least 14 days prior to the specified time and
place of payment. The ordinary shares that have been called upon and remain unpaid at the specified time are subject to forfeiture.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Redemption of Ordinary Shares.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The BVI Act provides that, subject to the memorandum and articles of a
company, shareholders holding 90% or more of all the voting ordinary shares in a company, may instruct the directors to redeem the ordinary
shares of the remaining shareholders. The directors shall be required to redeem the ordinary shares of the minority shareholders, whether
or not the shares are by their terms redeemable. The directors must notify the minority shareholders in writing of the redemption price
to be paid for the ordinary shares and the manner in which the redemption is to be effected. In the event that a minority shareholder
objects to the redemption price to be paid and the parties are unable to agree to the redemption amount payable, the BVI Act sets out
a mechanism whereby the shareholder and the company may each appoint an appraiser, who will together appoint a third appraiser and all
three appraisers will have the power to determine the fair value of the ordinary shares to be compulsorily redeemed. Pursuant to the BVI
Act, the determination of the three appraisers shall be binding on us and the minority shareholder for all purposes.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Variations of Rights of Ordinary Shares.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If at any time, there are different classes or series of ordinary shares
issued and outstanding, unless otherwise provided by the terms at the time of issuance of those ordinary shares of that class or series,
the rights and privileges attaching to any such class or series may, whether or not our company is being wound up, be varied with the
consent in writing of the holders of not less than three-fourths of the issued and outstanding ordinary shares of the class or series
and of the holders of not less than three-fourths of the issued and outstanding ordinary shares of any other class or series of shares
which may be adversely affected by such variation.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Differences in Corporate Law</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The BVI Act differs from laws generally applicable to United States corporations
and their shareholders. Set forth below is a brief summary of the significant differences between the provisions of the BVI Act applicable
to us and the laws applicable to companies incorporated in the United States and their shareholders. The discussion of the variations
does not cover any requirements of a stock exchange, trading medium or any applicable securities laws.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Protection for Minority Shareholders.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Under the laws of most U.S. jurisdictions, majority and controlling shareholders
of a company generally have certain &ldquo;fiduciary&rdquo; responsibilities to the minority shareholders. Corporate actions taken by
majority and controlling shareholders which are unreasonable and materially detrimental to the interest of minority shareholders may be
declared null and void. The rights of minority shareholders of British Virgin Islands companies will typically be governed by British
Virgin Islands law. These include the statutory right not to suffer the company's affairs to be conducted in a manner which is oppressive,
unfairly discriminatory or unfairly prejudicial in their capacity as shareholders, as well as certain protections at common law. The common
law of the British Virgin Islands (including as to the obligations of fiduciaries) is based on English common law. The availability and
interpretation of minority shareholder rights under British Virgin Islands law may differ from the position in the United States, even
in relation to laws which may appear to be analogous. Similarly, the exercise and enforcement of such rights may involve seeking remedies
under foreign law before a court or tribunal outside the United States, where the procedure and outcome may differ from what might apply
or eventuate in a court in the United States.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The BVI Act also provides that shareholders of the company owning 90% of
the votes entitled to be voted may cause the company to redeem the shares held by the remaining shareholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Powers of Directors.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The directors of a British Virgin Islands company, subject in certain cases
to the approval of the court (which will generally require shareholder approval), may implement the sale, transfer, exchange or disposition
of any asset, property, part of the business, or securities of the company, if the board determines such transaction to be in the best
interests of the company with the exception that shareholder approval may be required for any sale, transfer, lease exchange or other
disposition of more than 50% in value of the assets of the company other than in the usual or regular course of business of the company.
The BVI Act, however, provides that the memorandum and articles of a company may exclude application of the above shareholder approval
requirement for the disposition of 50% or more of the assets as set forth in Section 175 of the BVI Act. Our Memorandum and Articles incorporate
the exclusion; therefore our directors may act to sell or otherwise dispose of any or all the assets of our company without restriction
and without complying with section 175 of the BVI Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Directors appoint the officers and establish the responsibilities of
the officer positions.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The directors of a British Virgin Islands company may by resolution appoint
a person (who may also be a director) to be an officer or agent of the company.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Unlike in United States corporate law, subject to the memorandum and articles
of association of a BVI company, a director may appoint another person, who need not be a director, to be his alternate, provided such
person has consented in writing to be an alternate director. An alternate director has the same rights as the appointing director in relation
to any director&rsquo;s meeting and any written resolution circulated for written consent. Our Articles of Association prohibit the appointment
of alternate directors.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Any director that is a corporation or other entity may by resolution of
its directors or other governing body authorize a natural person to act as its representative at any meeting of the directors or of a
committee of directors, and the person so authorized shall be entitled to exercise the same powers on behalf of the corporation or other
entity which he represents as that corporation or entity could exercise if it were an individual director.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><I>Conflict of Interests.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Similar to the laws of most United States jurisdictions, when a director
of a BVI company becomes aware of the fact that he has an interest in a transaction which the company is to enter into, he must disclose
it to the board of directors. With sufficient disclosure of the interest in relation to that transaction, the director who is interested
in a transaction entered into or to be entered into by us may (i) vote on a matter relating to the transaction&#894; (ii) attend a meeting
of directors at which a matter relating to the transaction arises and be included in the quorum&#894; and (iii) sign a document on behalf
of us, or do any other thing in his capacity as a director, that relates to the transaction. If there is required disclosure by a director,
which is not made, then the transaction is voidable by us, unless the transaction is one that is an ordinary course transaction of our
company and the transaction is between us and the director or unless the material facts of the transaction are known by the shareholders
and the transaction is approved or ratified by a resolution of the shareholders or us received fair value for the transaction.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Written Consent and Cumulative Voting.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Under the British Virgin Islands law, shareholders are permitted to approve
matters by way of written resolution in place of a formal meeting. Our Memorandum and Articles provide that actions of the shareholders
may be taken in writing, including by telex, telegram, cable, facsimile or other written electronic communication, without the need for
any notice; provided, however, that where a written resolution of shareholders is passed without the written consent of a majority of
the shareholders (i.e., where for example it is passed by one shareholder holding 65% of the ordinary shares) a copy of such resolution
shall forthwith be sent to all shareholders not consenting to such resolution.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The BVI Act does not make a specific reference to cumulative voting, and
our current Memorandum and Articles have no provisions authorizing cumulative voting.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Independent Directors.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">There is no requirement for a majority, or for that matter any, of the
directors of the company to be independent under British Virgin Islands law.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Forfeiture of Ordinary Shares.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Although we intend to only sell our ordinary shares upon receipt of the
full purchase price, if ordinary shares are not fully paid, then under our Memorandum and Articles and the BVI Act any ordinary shares
that are not fully paid are subject to forfeiture. We have the right to demand full payment at any time, upon notice served on the shareholder
stating the time and amount due, and advising the shareholder that if the payment is not made then the ordinary shares will be forfeited
and cancelled. Any funds paid in respect of ordinary shares which are subsequently forfeited is non-refundable.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Redemption and Treasury Shares.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We may purchase, redeem or otherwise acquire and hold our own shares in
such manner and upon such other terms as the directors may agree with the relevant shareholder(s). Subject to the BVI Act, we may redeem
our ordinary shares only with the consent of the shareholders whose ordinary shares are to be redeemed, except that the consent from the
shareholders is not needed under the circumstances of the compulsory redemption, at the request of the shareholders holding 90% of the
votes of the outstanding ordinary shares entitled to vote, of the remaining issued ordinary shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Takeover Provisions.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The BVI Act does not provide anti-takeover measures, similar to some jurisdictions
in the United States. Generally speaking, our Memorandum and Articles do not introduce anti-takeover measures. For example, we have shareholder
action permitted by written consent, directors may be removed with or without cause, and we do not have staggered board appointments.
While we do not have any other class of equity authorized, which could have anti-takeover effect, we do have unlimited ordinary shares
and could use them for an anti-takeover plan or action, such as a poison pill plan, which would have to be in place before a takeover
offer is in contemplation, as, if not, the directors might be seen as exercising their powers for an improper purpose in trying to introduce
such a measure.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">Notwithstanding the foregoing, we could consider and adopt anti-takeover
measures. Some of these require an amendment to our Articles Association and/or Memorandum of Association, which would have to be approved
by way of director and/or shareholder resolutions.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Shareholder's Access to Corporate Records.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Similar to the corporate laws in the United States, a shareholder is entitled,
on giving written notice to the company, to inspect the company's (i) memorandum and articles of association&#894; (ii) register of members&#894;
(iii) register of directors&#894; and (iv) minutes of meetings and resolutions of members and of those classes of members of which he
is a member. A shareholder is also entitled to copies of the records. Notwithstanding the foregoing, the directors may limit access to
company records if it is contrary to the company interests. However, where a shareholder is denied access to the company records, the
shareholder may apply to the courts for an order to permit access and copying. We have not restricted the provisions of the BVI Act in
regard to access to the records of the company.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Indemnification.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Similar to the corporate law in the United States, British Virgin Islands
law does not limit the extent to which a company&rsquo;s memorandum and articles of association may provide for indemnification of officers
and directors, except to the extent any such provision may be held by the British Virgin Islands courts to be contrary to public policy,
such as to provide indemnification against civil fraud or the consequences of committing a crime.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our Memorandum and Articles provide for the indemnification of our directors
against all losses or liabilities incurred or sustained by a director as a director of our company in defending any proceedings, whether
civil or criminal and this indemnity only applies if he or she acted honestly and in good faith with a view to our best interests and,
with respect to any criminal action, he or she must have had no reasonable cause to believe his or her conduct was unlawful.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We may purchase and maintain insurance in relation to any person who is
or was a director, or who at the request of our company is or was serving as a director of, or in any other capacity is or was acting
for another body corporate or a partnership, joint venture, trust or other enterprise, against any liability asserted against the person
and incurred by the person in that capacity, whether or not we have or would have had the power to indemnify the person against the liability.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Mergers and Similar Arrangements.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The BVI Act, in Part IX, provides for the merger and other combination
arrangements for companies. In order to merge or consolidate, the directors of each constituent company must approve a written plan of
merger or consolidation which must be authorized by a resolution of shareholders.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">While a director may vote on a merger or consolidation even if he has a
financial interest in the plan of merger of consolidation, in order for the resolution to be valid and the transaction not voidable, the
interest must have been disclosed to the board of directors forthwith upon him becoming aware of such interest. The transaction will not
be voidable if the shareholders approve it.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Shareholders not otherwise entitled to vote on a merger or consolidation
may still acquire the right to vote if the plan of merger or consolidation contains any provision which, if proposed as an amendment to
the memorandum or articles of association, would entitle them to vote as a class or series on the proposed amendment. In any event, all
shareholders must be given a copy of the plan of merger or consolidation irrespective of whether they are entitled to vote at the meeting
or consent to the written resolution to approve the plan of merger or consolidation.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The shareholders of the constituent companies are not required to receive
shares of the surviving or consolidated company but may receive cash, debt obligations or other securities of the surviving or consolidated
company, or other assets, or a combination thereof. Further, some or all of the shares of a class or series may be converted into a kind
of asset while the other shares of the same class or series may receive a different kind of asset. As such, not all the shares of a class
or series must receive the same kind of consideration.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">After the plan of merger or consolidation has been approved by the directors
and authorized by a resolution of the shareholders, articles of merger or consolidation are executed by each company and filed with the
Registrar of Corporate Affairs in the British Virgin Islands.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A shareholder may dissent from a mandatory redemption of his shares, an
arrangement (if permitted by the court), a merger (unless the shareholder was a shareholder of the surviving company prior to the merger
and continues to hold the same or similar shares after the merger) and a consolidation. A shareholder properly exercising his dissenter
rights is entitled to payment of the fair value of their shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A shareholder dissenting from a merger or consolidation must object in
writing to the merger or consolidation before the vote by the shareholders on the merger or consolidation, unless notice of the meeting
was not given to the shareholder. If the merger or consolidation is approved by the shareholders, the company must within 20 days give
notice of this fact to each shareholder who gave written objection, and to each shareholder who did not receive notice of the meeting.
Such shareholders then have 20 days to give to the company their written election in the form specified by the BVI Act to dissent from
the merger or consolidation, provided that in the case of a merger, the 20 days starts when the plan of merger is delivered to the shareholder.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Upon giving notice of his election to dissent, a shareholder ceases to
have any rights of a shareholder except the right to be paid the fair value of his shares. As such, the merger or consolidation may proceed
in the ordinary course notwithstanding the dissent.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Within seven days of the later of the delivery of the notice of election
to dissent and the effective date of the merger or consolidation, the company must make a written offer to each dissenting shareholder
to purchase his shares at a specified price that the company determines to represent fair value. The company and the shareholder then
have 30 days to agree upon the price. If the company and the shareholder fail to agree on the price within the 30 days, then the company
and the shareholder shall each designate an appraiser and these two appraisers shall designate a third appraiser. These three appraisers
shall fix the fair value of the shares as of the close of business on the day before the shareholders approved the transaction without
taking into account any change in value as a result of the transaction.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><I>Shareholders&rsquo; Suits.</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Similar to the corporate laws in the United States, the BVI Act permits
derivative actions against its directors. However, the circumstances under which such actions may be brought, and the procedures and defenses
available under British Virgin Islands law may result in the rights of shareholders of a British Virgin Islands company being more limited
than those of shareholders of a company incorporated and/or existing in the United States.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The British Virgin Islands does not have provision for "class actions."
It does however provide for "representative action", whereby a representative may be appointed to represent parties with the
same interest. In such cases those parties will typically be bound by any decision in the proceedings. Section 184C(1) of the BVI Act
specifically provides for the process by which a claim may be brought "derivatively" on behalf of a company by one of its shareholders.
Importantly, proceedings may not be brought by a shareholder without leave of the court. The courts of the British Virgin Islands may,
on the application of a shareholder of a company, grant leave to that shareholder to bring proceedings in the name and on behalf of that
company, or intervene in proceedings to which the company is a party for the purpose of continuing, defending or discontinuing the proceedings
on behalf of the company. In determining whether to grant leave, the High Court of the British Virgin Islands must take into account (i)
whether the shareholder is acting in good faith. (ii) whether the derivative action is in the interests of the company taking account
of the views of the company's directors on commercial matters. (iii) whether the proceedings are likely to succeed, (iv) the costs of
the proceedings in relation to the relief likely to be obtained. and (v) whether an alternative remedy to the derivative claim is available.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Leave to bring or intervene in proceedings may be granted only if the High
Court of the British Virgin Islands is satisfied that (i) the company does not intend to bring, diligently continue or defend, or discontinue
the proceedings, as the case may be or (ii) it is in the interests of the company that the conduct of the proceedings should not be left
to the directors or to the determination of the shareholders as a whole.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>Anti-Takeover Effect of Authorized but Unissued Ordinary Shares</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The BVI Act does not require shareholder approval for any issuance of our
ordinary shares. The ordinary shares that may be issued under our Memorandum and Articles may be used for a variety of corporate purposes,
including future public offerings, to raise additional capital or to facilitate acquisitions. One of the effects of the existence of unissued
and unreserved ordinary shares may be to enable our board of directors to sell shares to persons friendly to current management, for such
consideration, in form and amount, as is acceptable to the board of directors, which issuance could render more difficult or discourage
an attempt to obtain control of us by means of a merger, tender offer, proxy contest or otherwise, and thereby protect the continuity
of our management and possibly deprive shareholders of opportunities to sell their ordinary shares at prices higher than prevailing market
prices.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>TAXATION</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><B>British Virgin Islands Tax Consequences</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">Under the law of the British Virgin Islands as
currently in effect, a holder of our ordinary shares who is not a resident of the British Virgin Islands is not liable for British Virgin
Islands income tax on dividends paid with respect to our ordinary shares, and all holders of our ordinary shares are not liable to the
British Virgin Islands for income tax on gains realized on the sale or disposal of securities. The British Virgin Islands does not impose
a withholding tax on dividends paid by a company incorporated or continued under the BVI Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">There are no capital gains, gift or inheritance
taxes levied by the British Virgin Islands on companies incorporated under the BVI Act. In addition, securities of companies incorporated
under the BVI Act are not subject to transfer taxes, stamp duties (unless such companies hold land in the BVI) or similar charges.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">There is no income tax treaty or convention currently
in effect between (i) the United States and the British Virgin Islands or (ii) Canada and the British Virgin Islands, although a Tax Information
Exchange Agreement is in force between the United States and the BVI and Canada and the BVI.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;&nbsp;</FONT><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><I>The BVI Economic Substance (Companies and Limited
Partnership) Act (Revised Edition 2020) (the &ldquo;<B>ESA</B>&rdquo;)</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">The above legislation is aimed at addressing concerns
raised by the Council of the European Union as to offshore structures engaged in certain activities, which attract profits without real
economic activity provides (among other things) that BVI companies that carry out certain defined activities, need to take steps to establish
substance in the British Virgin Islands. We have filed all our economic substance declarations when due in accordance with the requirements
of the legislation. We are not currently subject to any requirements to establish economic substance in the BVI and given the nature of
our business and assets at the current time, the ESA has little material impact on us and our operations. However, the legislation is
still in its early stages and therefore remains subject to further clarification and interpretation.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><B>U.S. Federal Income Tax Consequences</B></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">The discussion below is for general information
only and is not, and should not be interpreted to be, tax advice to any holder of our ordinary shares. Each holder or a prospective holder
of our ordinary shares is urged to consult his, her or its own tax advisor.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white"><I>&nbsp;</I></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><I>General</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">This section is a general summary of the material
United States federal income tax consequences of the ownership and disposition of our ordinary shares. This summary is based on the provisions
of the Internal Revenue Code of 1986, as amended (the &ldquo;<B>Code</B>&rdquo;), the applicable Treasury regulations promulgated and
proposed thereunder, judicial decisions and current administrative rulings and practice, all of which are subject to change, possibly
on a retroactive basis. The summary applies to you only if you hold our ordinary shares as a capital asset within the meaning of Section
1221 of the Code. The United States Internal Revenue Service (the &ldquo;<B>IRS</B>&rdquo;), may challenge the tax consequences described
below, and we have not requested, nor will we request, a ruling from the IRS or an opinion of counsel with respect to the United States
federal income tax consequences of ownership or disposition of our ordinary shares. This summary does not purport to be a comprehensive
description of all the tax considerations that may be relevant to the ownership of our ordinary shares. In particular, the discussion
below does not cover tax consequences that depend upon your particular tax circumstances nor does it cover any state, local or non-United
States law, or the possible application of the United States federal estate or gift tax. You are urged to consult your own tax advisors
regarding the application of the United States federal income tax laws to your particular situation as well as any state, local, non-United
States and United States federal estate and gift tax consequences of the ownership and disposition of our ordinary shares. In addition,
this summary does not take into account any special United States federal income tax rules that may apply to a particular holder of our
ordinary shares, including, without limitation, the following:</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a dealer in securities;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a trader in securities that elects to use a mark-to-market method of accounting for its securities holdings;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a financial institution or a bank;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an insurance company;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a tax-exempt organization;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a person that holds our ordinary shares in a hedging transaction or as part of a straddle or a conversion
transaction;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a person whose functional currency for United States federal income tax purposes is not the U.S. dollar;&#9;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a person liable for alternative minimum tax;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a person that owns, or is treated as owning, 10% or more, by voting power or value, of our ordinary shares;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">certain former U.S. citizens and residents who have expatriated; or&#9;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a person who receives our ordinary shares pursuant to the exercise of employee stock options or otherwise
as compensation.&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><I>U.S. Holders</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">For purposes of the discussion below, you are
a &ldquo;U.S. Holder&rdquo; if you are a beneficial owner of our ordinary shares who or which is:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an individual United States citizen or resident alien of the United States (as specifically defined for
United States federal income tax purposes);</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a corporation, or other entity treated as a corporation for United States federal income tax purposes,
created or organized in or under the laws of the United States, any State or the District of Columbia;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">an estate whose income is subject to United States federal income tax regardless of its source; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">a trust (x) if a United States court can exercise primary supervision over the trust's administration
and one or more United States persons are authorized to control all substantial decisions of the trust or (y) if it was in existence on
August 20, 1996, was treated as a United States person prior to that date and has a valid election in effect under applicable Treasury
regulations to be treated as a United States person.&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">If a partnership holds our ordinary shares, the
tax treatment of a partner will generally depend upon the status of the partner and upon the activities of the partnership. If you are
a partner of a partnership holding our ordinary shares, you should consult your tax advisor.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><U>Distributions</U></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">In general, subject to the passive foreign investment
company (&ldquo;<B>PFIC</B>&rdquo;) rules discussed below, the gross amount of any distribution received by a U.S. Holder with respect
to our ordinary shares will be included in the gross income of the U.S. Holder as a dividend to the extent attributable to our current
and accumulated earnings and profits, as determined under U.S. federal income tax principles. Unless we maintain calculations of our earnings
and profits in accordance with U.S. federal income tax principles, U.S. Holders should expect that any distribution will generally be
treated as a dividend for U.S. federal income tax purposes. Any dividends from us will not be eligible for the dividends-received deduction
generally allowed to corporations in respect of dividends received from U.S. corporations. For U.S. foreign tax credit purposes, dividends
received on our ordinary shares by a U.S. Holder will generally be treated as income from sources outside the United States and will generally
constitute &ldquo;passive category income.&rdquo; A portion of such dividends, however, will be treated as U.S. source income, subject
to certain exceptions, in proportion to our U.S. source earnings and profits if U.S. persons collectively own, directly or indirectly,
50% or more of the voting power or value of our ordinary shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; background-color: white">U.S. Holders that are individuals and certain
other non-corporate U.S. Holders will be subject to tax on dividend income from a &ldquo;qualified foreign corporation&rdquo; at preferential
rates of taxation provided that certain holding period and other requirements are met. For this purpose, a foreign corporation (other
than a corporation that is classified as a PFIC (as discussed below) for the taxable year in which the dividend is paid or the preceding
taxable year) will generally be considered to be a qualified foreign corporation (i) if it is eligible for the benefits of a comprehensive
tax treaty with the United States which the Secretary of Treasury of the United States determines is satisfactory for purposes of this
provision and which includes an exchange of information program, or (ii) with respect to any dividend it pays on stock which is readily
tradable on an established securities market in the United States. Our ordinary shares are listed on Nasdaq, which is an established securities
market in the United States, and are expected to be readily tradable. Thus, we expect that dividends paid on our ordinary shares will
meet the conditions above required for the preferential tax rates, provided we are not a PFIC in the year such dividend is paid or the
preceding taxable year.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><FONT STYLE="font-size: 10pt">&nbsp;</FONT><FONT STYLE="font-size: 12pt">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><U>Sale, Exchange or Other Taxable Disposition</U></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">Subject to the PFIC rules discussed below, upon
a sale, exchange or other taxable disposition of our ordinary shares, a U.S. Holder will generally recognize a capital gain or loss equal
to the difference between the amount realized on such sale, exchange or other taxable disposition and the adjusted tax basis of such ordinary
shares. As discussed above, a U.S. Holder&rsquo;s initial tax basis in our ordinary shares will generally equal the fair market value
on the distribution date of such shares. Such gain or loss will be a long-term capital gain or loss if our ordinary shares have been held
for more than one year and will be a short-term gain or loss if the holding period is equal to or less than one year. Such gain or loss
will generally be considered U.S. source gain or loss for U.S. foreign tax credit purposes. Long-term capital gains of certain non-corporate
U.S. Holders are eligible for reduced rates of taxation. For both corporate and non-corporate U.S. Holders, limitations apply to the deductibility
of capital losses.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><U>Passive Foreign Investment Company (PFIC)</U></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Under the Code, we will be a PFIC for any taxable year in which, after
the application of certain &ldquo;look-through&rdquo; rules with respect to related companies, either (i) 75% or more of our gross income
consists of &ldquo;passive income,&rdquo; or (ii) 50% or more of the average quarterly value of our assets consist of assets that produce,
or are held for the production of, &ldquo;passive income.&rdquo; Passive income generally includes interest, dividends, rents, rents and
royalties other than certain rents and royalties which are received from unrelated parties in connection with the active conduct of a
trade or business, and capital gains. Whether we will be a PFIC in any year depends on the composition of our income and assets, and the
relative fair market value of our assets from time to time, which we expect may vary substantially over time. We must make a separate
determination each year as to whether we are a PFIC. As a result, our PFIC status may change from year to year based on our income and
assets. <FONT STYLE="color: #212529; background-color: white">We believe we were a PFIC for the fiscal year ended in 2018 and the fiscal
years ended March 31, 2023 and 2024, and we expect to be a PFIC for the fiscal year ending March 31, 2025. We may have been a PFIC in
other years and we may be a PFIC in the future.</FONT></P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; background-color: white">

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">If we are a PFIC for any fiscal year during which
a U.S. Holder holds our ordinary shares, we generally will continue to be treated as a PFIC with respect to that U.S. Holder for all succeeding
fiscal years during which the U.S. Holder holds our ordinary shares, unless we cease to meet the threshold requirements for PFIC status&nbsp;and&nbsp;that
U.S. Holder makes a qualifying &ldquo;deemed sale&rdquo; election with respect to the ordinary shares. If such an election is made, the
U.S. Holder will be deemed to have sold the ordinary shares it holds at their fair market value on the last day of the last fiscal year
in which we qualified as a PFIC, and any gain from such deemed sale will be subject to the consequences described below. After the deemed
sale election, the ordinary shares with respect to which the deemed sale election was made will not be treated as shares in a PFIC unless
we subsequently become a PFIC.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">If we are a PFIC for any taxable year during which
a U.S. Holder holds our ordinary shares, the U.S. Holder may be subject to adverse tax consequences. Generally, gain recognized upon a
disposition of our ordinary shares by the U.S. Holder would be allocated ratably over the U.S. Holder's holding period for such ordinary
shares. The amounts allocated to the taxable year of disposition and to years before we became a PFIC would be taxed as ordinary income.
The amount allocated to each other taxable year would be subject to tax at the highest rate in effect for that taxable year for individuals
or corporations, as appropriate, and would be increased by an additional tax equal to interest on the resulting tax deemed deferred with
respect to each such other taxable year. Further, to the extent that any distribution received by a U.S. Holder on our ordinary shares
exceeds 125% of the average of the annual distributions on such ordinary shares received during the preceding three years or the U.S.
Holder's holding period, whichever is shorter, that distribution would be subject to taxation in the same manner described immediately
above with respect to gain on disposition.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; background-color: white">If we are a PFIC for any fiscal year during which
any of our non-U.S. subsidiaries is also a PFIC, a U.S. Holder of our ordinary shares during such year will be treated as owning a proportionate
amount (by value) of the shares of the lower-tier PFIC for purposes of the application of these rules to such subsidiary. U.S. Holders
should consult their tax advisers regarding the tax consequences if the PFIC rules apply to any of our subsidiaries. Alternatively, if
we are a PFIC and if our ordinary shares are &ldquo;regularly traded&rdquo; on a &ldquo;qualified exchange,&rdquo; a U.S. Holder may be
eligible to make a mark-to-market election that would result in tax treatment different from the general tax treatment described above.
Our ordinary shares would be treated as &ldquo;regularly traded&rdquo; in any calendar year in which more than a de minimis quantity of
the ordinary shares are traded on a qualified exchange on at least 15 days during each calendar quarter. Nasdaq is a qualified exchange
for this purpose. However, because a mark-to-market election cannot be made for equity interests in any lower-tier PFIC that we may own,
a U.S. Holder that makes a mark-to-market election with respect to us may continue to be subject to the PFIC rules with respect to any
indirect investments held by us that are treated as an equity interest in a PFIC for U.S. federal income tax purposes. If a U.S. Holder
makes the mark-to-market election, the U.S. Holder generally will recognize as ordinary income any excess of the fair market value of
the ordinary shares at the end of each taxable year over their adjusted tax basis, and will recognize an ordinary loss in respect of any
excess of the adjusted tax basis of the ordinary shares over their fair market value at the end of the taxable year (but only to the extent
of the net amount of income previously included as a result of the mark-to-market election). If a U.S. Holder makes the election, the
U.S. Holder's tax basis in the ordinary shares will be adjusted to reflect these income or loss amounts. Any gain recognized on the sale
or other disposition of our ordinary shares in a year when we are a PFIC will be treated as ordinary income and any loss will be treated
as an ordinary loss (but only to the extent of the net amount of income previously included as a result of the mark-to-market election).
If a U.S. Holder makes a mark-to-market election it will be effective for the taxable year for which the election is made and all subsequent
taxable years unless our ordinary shares are no longer regularly traded on a qualified exchange or the IRS consents to the revocation
of the election. U.S. Holders are urged to consult their tax advisers about the availability of the mark-to-market election, and whether
making the election would be advisable in their particular circumstances.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">Alternatively, a U.S. Holder of stock in a PFIC
may make a so-called &ldquo;Qualified Electing Fund&rdquo; election to avoid the PFIC rules regarding distributions and gain described
above. The PFIC taxation regime would not apply to a U.S. Holder who makes a QEF election for all taxable years that such U.S. Holder
has held our ordinary shares while we are a PFIC, provided that we comply with specified reporting requirements. Instead, each U.S. Holder
who has made a valid and effective QEF election is required for each taxable year that we are a PFIC to include in income such U.S. Holder&rsquo;s
pro rata share of our ordinary earnings as ordinary income and such U.S. Holder's pro rata share of our net capital gains as long-term
capital gain, regardless of whether we make any distributions of such earnings or gain. In general, a QEF election is effective only if
we make available certain required information. U.S. Holders should be aware, however, that we are not required to make this information
available but have agreed to do so for prior fiscal years for those U.S. Holders who ask for it. The QEF election is made on a shareholder-by-shareholder
basis and generally may be revoked only with the consent of the IRS. U.S. Holders should consult with their own tax advisors regarding
eligibility, manner and advisability of making a QEF election if we are treated as a PFIC.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">In addition, if we are a PFIC or, with respect
to particular U.S. Holders, are treated as a PFIC for the taxable year in which we paid a dividend or for the prior taxable year, the
preferential rates discussed above with respect to dividends paid to certain non-corporate U.S. Holders would not apply.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">If a U.S. Holder owns our ordinary shares during
any year in which we are a PFIC, the U.S. Holder generally will be required to file an IRS Form 8621 (Information Return by a Shareholder
of a Passive Foreign Investment Company or Qualified Electing Fund) with respect to us, generally with the U.S. Holder's federal income
tax return for that year. If we are a PFIC for a given taxable year, you should consult your tax advisor concerning your annual filing
requirements.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><B>The U.S. federal income tax rules relating
to PFICs are complex. U.S. Holders are urged to consult their own tax advisers with respect to the ownership and disposition of our ordinary
shares, the consequences if we are or become a PFIC, any elections available with respect to our ordinary shares, and the IRS information
reporting obligations with respect to the ownership and disposition of our ordinary shares.</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"></P>

<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; background-color: white"><U>Foreign asset reporting</U></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">Certain U.S. Holders, who are individuals, are
required to report information relating to an interest in ordinary shares, subject to certain exceptions (including an exception for ordinary
shares held in accounts maintained by U.S. financial institutions). U.S. Holders are urged to consult their tax advisors regarding their
information reporting obligations, if any, with respect to their ownership and disposition of ordinary shares.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><I>Non-U.S. Holders</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">If you are not a U.S. Holder, you are a &ldquo;Non-U.S.
Holder.&rdquo;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><U>Distributions on Our Ordinary Shares</U></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">You generally will not be subject to U.S. federal
income tax, including withholding tax, on distributions made on our ordinary shares unless:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">you conduct a trade or business in the United States; and&#9;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the distributions are effectively connected with the conduct of that trade or business (and, if an applicable
income tax treaty so requires as a condition for you to be subject to U.S. federal income tax on a net income basis in respect of income
from our ordinary shares, such distributions are attributable to a permanent establishment that you maintain in the United States).&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">If you meet the two tests above, you generally
will be subject to tax in respect of such dividends in the same manner as a U.S. Holder, as described above. In addition, any effectively
connected dividends received by a non-U.S. corporation may also, under certain circumstances, be subject to an additional &ldquo;branch
profits tax&rdquo; at a 30 percent rate or such lower rate as may be specified by an applicable income tax treaty.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><U>Sale, Exchange or Other Disposition of Our
Ordinary Shares</U></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">Generally, you will not be subject to U.S. federal
income tax, including withholding tax, in respect of gain recognized on a sale or other taxable disposition of our ordinary shares unless:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">your gain is effectively connected with a trade or business that you conduct in the United States (and,
if an applicable income tax treaty so requires as a condition for you to be subject to U.S. federal income tax on a net income basis in
respect of gain from the sale or other disposition of our ordinary shares, such gain is attributable to a permanent establishment maintained
by you in the United States); or &#9;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">you are an individual Non-U.S. Holder and are present in the United States for at least 183 days in the
taxable year of the sale or other disposition, and certain other conditions exist.&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">If you meet one of tests above, you generally
will be subject to tax in respect of any gain effectively connected with your conduct of a trade or business in the United States in the
same manner as a U.S. Holder, as described above. Effectively connected gains realized by a non-U.S. corporation may also, under certain
circumstances, be subject to an additional &ldquo;branch profits tax&rdquo; at a rate of 30 percent or such lower rate as may be specified
by an applicable income tax treaty.</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white"><B><I></I></B></P>

<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify; text-indent: 23.05pt; background-color: white"><B><I>&nbsp;</I></B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white"><I>Backup Withholding and Information Reporting</I></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 23.05pt; margin: 0pt 0; background-color: white">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">Payments, including dividends and proceeds of
sales, in respect of our ordinary shares that are made in the United States or by a United States related financial intermediary may be
subject to United States information reporting rules. In addition, U.S. Holders may be subject to United States federal backup withholding
tax. U.S. Holders will not be subject to backup withholding provided that:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0; background-color: white">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">you are a corporation or other exempt recipient; or</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">you provide your correct United States federal taxpayer identification number and certify, under penalties
of perjury, that you are not subject to backup withholding.&nbsp;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Amounts withheld under the backup withholding rules may be credited against your United States
federal income tax, and you may obtain a refund of any excess amounts withheld under the backup withholding rules by filing the appropriate
claim for refund with the IRS in a timely manner.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"><BR STYLE="clear: both">
</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>PLAN OF DISTRIBUTION</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We are registering the Shares on behalf of the Selling Shareholders named
herein. The Selling Shareholders and any of their pledgees, assignees and successors-in-interest may, from time to time, on a continuous
or delayed basis, sell any or all of the Shares covered by this prospectus directly to one or more purchasers or through brokers, dealers
or underwriters who may act solely as agents at market prices prevailing at the time of sale, at prices related to the prevailing market
prices, at negotiated prices, or at fixed prices, which may be changed on any stock exchange, market or trading facility on which our
ordinary shares are traded or in private transactions. The sale of the Selling Shareholders&rsquo; Shares offered by this prospectus may
be effected in one or more of the following methods:</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">transactions involving cross or block trades;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">purchases by a broker-dealer as principal and resale by the broker-dealer for its account;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">exchange distributions in accordance with the rules of the applicable exchange;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">privately negotiated transactions;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">short sales after the registration statement of which this prospectus forms a part becomes effective;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">transactions through broker-dealers to sell a specified number of such securities at a stipulated price
per share;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">through the writing or settlement of options or other hedging transactions, whether through an options
exchange or otherwise;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">&ldquo;at the market&rdquo; into an existing market for our common shares;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">through the writing of options on the securities;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">a combination of any such methods of sale; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">&bull;</TD><TD STYLE="text-align: justify">any other method permitted pursuant to applicable law.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">In order to comply with the securities laws of certain states, if applicable,
the Shares of the Selling Shareholders may be sold only through registered or licensed brokers or dealers. In addition, in certain states,
such Shares may not be sold unless they have been registered or qualified for sale in the state or an exemption from the registration
or qualification requirement is available and complied with.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Selling Shareholders may also sell or transfer their Shares pursuant
to any available exemption from the registration requirements of the Securities Act, including under Rule 144 promulgated under the Securities
Act, or Rule 144, if available, rather than under this prospectus. In addition, the Selling Shareholders may transfer their securities
by other means not described in this prospectus.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Selling Shareholders may also sell their Shares directly to market
makers acting as principals and/or broker-dealers acting as agents for themselves or their customers. Such broker-dealers may receive
compensation in the form of discounts, concessions or commissions from the Selling Shareholders and/or the purchasers of such securities
for whom such broker-dealers may act as agents or to whom they sell as principal or both, which compensation as to a particular broker-dealer
might be in excess of customary commissions. Market makers and block purchasers purchasing the Shares will do so for their own account
and at their own risk. It is possible that the Selling Shareholders will attempt to sell their Shares in block transactions to market
makers or other purchasers at a price per share that may be below the then market price.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Brokers, dealers, underwriters or agents participating in the distribution
of the Shares held by the Selling Shareholders as agents may receive compensation in the form of commissions, discounts or concessions
from the Selling Shareholders and/or purchasers of the Shares for whom the broker-dealers may act as agent. The Selling Shareholders may
agree to indemnify any agent, dealer or broker-dealer that participates in transactions involving sales of their Shares if liabilities
are imposed on that person under the Securities Act.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The Selling Shareholders have advised us that they have not entered into
any agreements, understandings or arrangements with any underwriters or broker-dealers regarding the sale of their Shares, nor is there
an underwriter or coordinating broker acting in connection with a proposed sale of Shares by the Selling Shareholders. If we are notified
by the Selling Shareholders that any material arrangement has been entered into with a broker-dealer for the sale of Shares if required,
we will file a supplement to this prospectus.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">In connection with the sale of the Shares or interests therein, the Selling
Shareholders may enter into hedging transactions with broker-dealers or other financial institutions, which may in turn engage in short
sales of the Shares in the course of hedging the positions they assume. The Selling Shareholders may also sell their Shares short and
deliver these Shares to close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these
Shares. The Selling Shareholders may also enter into option or other transactions with broker-dealers or other financial institutions
or create one or more derivative securities that require the delivery to such broker-dealer or other financial institution of securities
offered by this prospectus, which Shares such broker-dealer or other financial institution may resell pursuant to this prospectus (as
supplemented or amended to reflect such transaction).</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">With regard only to any Shares it sells for its own behalf, each Selling
Shareholder may be deemed an &ldquo;underwriter&rdquo; within the meaning of the Securities Act. This offering as it relates to each Selling
Shareholder will terminate on the date that all Shares offered by such Selling Shareholder pursuant to this prospectus have been sold.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We may suspend the sale of Shares by the Selling Shareholders pursuant
to this prospectus for certain periods of time for certain reasons, including if the prospectus is required to be supplemented or amended
to include additional material information.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">If the Selling Shareholders use this prospectus for any sale of their Shares,
the Selling Shareholders will be subject to the prospectus delivery requirements of the Securities Act.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We will pay the expenses in connection with the registration of the Shares
being registered hereunder. We have agreed to indemnify the Selling Shareholders against certain losses, claims, damages and liabilities
in accordance with the Securities Purchase Agreement.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We agreed to use commercially reasonable efforts to keep this registration
statement continuously effective under the Securities Act, and prepare and file prospectus supplements that includes any information previously
omitted from the prospectus filed as part of the initial registration statement and pre- and post-effective amendments as necessary, until
the date that all of the securities have been sold thereunder or pursuant to Rule 144.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The anti-manipulation rules of Regulation M under the Exchange Act may
apply to sales of our ordinary shares and activities of the Selling Shareholders.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">While the Selling Shareholders are engaged in a distribution of the Shares
included in this prospectus they are required to comply with Regulation M promulgated under the Exchange Act. With certain exceptions,
Regulation M precludes the Selling Shareholders, any affiliated purchasers, and any broker-dealer or other person who participates in
the distribution from bidding for or purchasing, or attempting to induce any person to bid for or purchase any security that is the subject
of the distribution until the entire distribution is complete. Regulation M also prohibits any bids or purchases made in order to stabilize
the price of a security in connection with the distribution of that security. All of the foregoing may affect the marketability of the
shares offered hereby this prospectus.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>EXPENSES</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-indent: 24pt; margin: 0pt 0">The following are the estimated expenses of this offering payable by us with
respect to the issuance and distribution of the Shares covered by the registration statement of which this prospectus forms a part. With
the exception of the SEC registration fee, all amounts are estimates and may change:</P>

<P STYLE="font-size: 10pt; text-indent: 24pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 85%; font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">SEC registration fee</TD><TD STYLE="width: 1%; font-size: 10pt">&nbsp;</TD>
    <TD STYLE="width: 1%; font-size: 10pt; text-align: left">$</TD><TD STYLE="width: 12%; font-size: 10pt; text-align: right">3,013.84</TD><TD STYLE="white-space: nowrap; width: 1%; font-size: 10pt; text-align: left">*</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Legal fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">50,000.00</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; text-align: left; text-indent: -10pt; padding-left: 10pt">Accountants&rsquo; fees and expenses</TD><TD STYLE="font-size: 10pt">&nbsp;</TD>
    <TD STYLE="font-size: 10pt; text-align: left">$</TD><TD STYLE="font-size: 10pt; text-align: right">16,995.00</TD><TD STYLE="white-space: nowrap; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; padding-bottom: 1pt; text-indent: -10pt; padding-left: 10pt">Miscellaneous</TD><TD STYLE="font-size: 10pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 1pt solid; font-size: 10pt; text-align: right">10,000.00</TD><TD STYLE="white-space: nowrap; border-bottom: Black 1pt solid; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-size: 10pt; font-weight: bold; padding-bottom: 2.25pt; text-indent: -10pt; padding-left: 10pt">Total</TD><TD STYLE="font-size: 10pt; padding-bottom: 2.25pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.25pt double; font-size: 10pt; text-align: right">80,008.84</TD><TD STYLE="white-space: nowrap; border-bottom: Black 2.25pt double; font-size: 10pt; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: left"><FONT STYLE="background-color: white">* Previously paid.</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 40 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>ENFORCEABILITY OF CIVIL LIABILITIES</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We are incorporated in the British Virgin Islands. There may be perceived
disadvantages for investors that accompany incorporation in the British Virgin Islands, which may include the facts that the British Virgin
Islands has a less developed body of securities laws as compared to the United States providing significantly less protection to investors.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our organizational documents do not contain provisions requiring disputes
be submitted to arbitration, including those arising under the securities laws of the United States, between us, our officers, directors
and shareholders. Therefore, actions in these controversies will have to be heard in formal court forums, which may be more costly and
less flexible, and laws, interpretations and precedent may or may not be consistent or available.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">An important part of our operations is conducted and a significant portion
of our assets is located outside the United States. Some of our directors and officers are nationals or residents of jurisdictions other
than the United States, and some or all of their assets are located outside the United States. As a result, it may be difficult or impossible
for a shareholder to bring an original action against us or those persons in a British Virgin Islands or other court in the event that
a shareholder believes that his or her rights have been infringed under the United States federal securities laws or otherwise. It may
also be difficult for a shareholder to enforce in United States courts judgments obtained in United States courts based on the civil liability
provisions of the United States federal securities laws against us and our officers and directors, some of whom are not residents of the
United States and whose assets are located outside of the United States. In addition, there is uncertainty as to whether the courts of
the British Virgin Islands would recognize or enforce judgments of United States courts against us or those persons predicated upon the
civil liability provisions of the securities laws of the United States or any state. There is no statutory recognition in the British
Virgin Islands of judgments obtained in the United States, although the courts of the British Virgin Islands will generally recognize
and enforce a non-penal judgment of a foreign court of competent jurisdiction without retrial on the merits. It is uncertain whether British
Virgin Islands courts would be competent to hear original actions brought in the British Virgin Islands against us or those persons predicated
upon the securities laws of the United States or any state.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our corporate affairs are governed by our Memorandum and Articles and by
the BVI Act and common law. The rights of shareholders to take legal action against our directors and us, actions by minority shareholders
and the fiduciary responsibilities of our directors to us under British Virgin Islands law are to a large extent governed by common law,
the BVI Act, court procedures and other relevant regulation. The jurisprudence of the British Virgin Islands is derived in part from comparatively
limited judicial precedent in the British Virgin Islands as well as from English common law, which has persuasive, but not binding, authority
on a court in the British Virgin Islands. The rights of our shareholders and the fiduciary responsibilities of our directors under British
Virgin Islands law are not as clearly established as they would be under statutes or judicial precedents in the United States. In particular,
the British Virgin Islands has no securities laws as compared to the United States, and provides less protection to investors in many
instances. In addition, British Virgin Islands companies may not have standing to initiate a shareholder derivative action before the
federal courts of the United States.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">As a result of all of the above, our shareholders may have more difficulties
in protecting their interests through actions against our management, directors or major shareholders than would shareholders of a corporation
incorporated and operating in a jurisdiction in the United States.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Forbes Hare LLP, our counsel as to British Virgin Islands law, has advised
us that there is uncertainty as to whether the courts of the British Virgin Islands would:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">recognize or enforce judgments of United States courts obtained against us or our directors or officers
predicated upon the civil liability provisions of the securities laws of the United States or any state in the United States; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">entertain original actions brought in each respective jurisdiction against us or our directors or officers
predicated upon the securities laws of the United States or any state in the United States.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Forbes Hare LLP has further advised us that the United States and the British
Virgin Islands do not have a treaty providing for reciprocal recognition and enforcement of judgments of United States courts in civil
and commercial matters and that a final judgment for the payment of money rendered by any federal or state court in the United States
based on civil liability, whether or not predicated solely upon the United States federal securities laws, would not be automatically
enforceable in the British Virgin Islands. We have also been advised that any final and conclusive monetary judgment for a definite sum
obtained against us in United States federal or state courts would be treated by the courts of the British Virgin Islands as a cause of
action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary provided that:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(i)</TD><TD STYLE="text-align: justify">the United States federal or state court had jurisdiction in the matter and we either submitted to such
jurisdiction or was resident or carrying on business within such jurisdiction and was duly served with process;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(ii)</TD><TD STYLE="text-align: justify">the judgment given by the United States federal or state court was not in respect of penalties, taxes,
fines or similar fiscal or revenue obligations;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(iii)</TD><TD STYLE="text-align: justify">the judgment was not procured by fraud;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(iv)</TD><TD STYLE="text-align: justify">recognition or enforcement of the judgment in the British Virgin Islands would not be contrary to public
policy; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.5in">(v)</TD><TD STYLE="text-align: justify">the proceedings pursuant to which judgment was obtained were not contrary to natural justice.</TD></TR></TABLE>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">A British Virgin Islands court may impose civil liability on us or our
directors or officers in a suit brought in the courts of the British Virgin Islands against us or these persons with respect to a violation
of United States federal securities laws, provided that the facts surrounding any violation constitute or give rise to a cause of action
under British Virgin Islands law.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We have appointed Dr. Ian Walters as our agent to receive service of process
with respect to any action brought against us in the United States under the federal securities laws of the United States.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 42 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>LEGAL MATTERS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The validity of the securities offered hereby will be passed upon for us
by Forbes Hare LLP, our British Virgin Islands counsel. Certain other legal matters will be passed upon for us by Hogan Lovells US LLP.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>EXPERTS</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">Our consolidated financial statements, appearing in our Form 20-F Annual
Report filed with the SEC on August 14, 2024, as of March 31, 2024 and 2023, and for each of the three years in the period ended March
31, 2024, incorporated by reference in this prospectus, have been audited by Marcum LLP, an independent registered public accounting firm,
as stated in its report appearing therein. The audited consolidated financial statements are incorporated herein by reference in reliance
upon such report, which includes an explanatory paragraph as to our ability to continue as a going concern, given on the authority of
such firm as experts in accounting and auditing.</P>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><B>Where You Can Find More Information</B></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We have filed with the SEC a registration statement on Form F-1 and relevant
exhibits and schedules, under the Securities Act covering the ordinary shares to be sold in this offering. This prospectus, which constitutes
a part of the registration statement, summarizes material provisions of contracts and other documents that we refer to in this prospectus.
Since this prospectus does not contain all of the information contained in the registration statement, you should read the registration
statement and its exhibits and schedules for further information with respect to us and our ordinary shares. We file annual reports on
Form 20-F and other information with the SEC and furnish or file reports on Form 6-K to the SEC. Our SEC filings, including the registration
statement, are available to you on the SEC&rsquo;s website at http://www.sec.gov.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">We are subject to the information reporting requirements of the Exchange
Act that are applicable to foreign private issuers, and under those requirements we file reports with the SEC. Those reports or other
information may be inspected without charge at the website listed above.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</B></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">The SEC allows us to &ldquo;incorporate by reference&rdquo; information
in this prospectus, which means that we can disclose important information to you by referring you to another document filed separately
with the SEC. The information incorporated by reference is deemed to be part of this prospectus. Any statement contained in a previously
filed or furnished document that is incorporated by reference will be deemed to be modified or superseded for purposes of this prospectus
to the extent that a statement contained in this prospectus modifies or replaces that statement.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">This prospectus incorporates by reference the documents set forth below
that have previously been filed with or furnished to the SEC:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify"> Annual Report on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1095435/000117184324004800/f20f_081224.htm">Form 20-F</A> for the fiscal year ended March 31, 2024 filed with the SEC on August 14,
2024;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.15pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">our
Reports on Form 6-K filed with the SEC on <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324001997/f6k_041224.htm">April 12, 2024</A>, <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324002370/f6k_043024.htm">May 1, 2024</A> and <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324004725/f6k_081224.htm">August 13, 2024</A>; and</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">the description of our ordinary shares contained in our registration statement on <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000106299321001661/form8a12b.htm">Form 8-A</A> filed with the SEC on February 18, 2021, as updated by <A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184322005215/exh_21.htm">Exhibit 2.1</A> to our Annual Report on Form 20-F for the fiscal year ended March 31, 2022 filed with the SEC on August 1, 2022, and any amendment
or report filed for the purpose of further updating that description.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><FONT STYLE="background-color: white">We will provide, without charge,
to each person, including any beneficial owner, to whom this prospectus is delivered, on the written or oral request of such person, a
copy of any or all of the reports or documents incorporated by reference in this prospectus, but not delivered with this prospectus. Any
request may be made by writing or telephoning us at the following address or telephone number:</FONT></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><FONT STYLE="background-color: white">&nbsp;</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="background-color: white">Portage Biotech Inc.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="background-color: white">Attention: Investor Relations</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="background-color: white">c/o Portage Development Services Inc.</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">59<FONT STYLE="background-color: white"> Wilton Road, Westport, Connecticut
06880</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="background-color: white">(203) 221-7378</FONT></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">In addition, copies of any or all of the documents incorporated herein by reference may be accessed
at our website at www.portagebiotech.com. The information on such website is not incorporated by reference and is not a part of this prospectus.<BR STYLE="clear: both">
</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><IMG SRC="logo.jpg" ALT="">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center"><B>Portage Biotech Inc.</B></P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center"><B>481,581 Ordinary Shares underlying Warrants</B></P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 12pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center"><B>PROSPECTUS </B></P>

<P STYLE="margin: 0pt 0; font-size: 12pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 12pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 12pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0 0pt 0.5in; font-size: 12pt; text-align: center"><B>, 2024</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;<BR STYLE="clear: both">
</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B></B></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>PART II</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>INFORMATION NOT REQUIRED IN THE PROSPECTUS</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Item 6. Indemnification of Directors and Officers</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Exculpation, Insurance and Indemnification of Directors and Officers</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0">British Virgin Islands law does not limit the extent to which a company&rsquo;s memorandum and
articles of association may provide for indemnification of officers and directors, except to the extent any such provision may be held
by the British Virgin Islands courts to be contrary to public policy, such as to provide indemnification against civil fraud or the consequences
of committing a crime. In addition, a company may only indemnify a person who acted honestly and in good faith and in what he or she believed
to be in the best interests of the company, and in the case of criminal proceedings, the person had no reasonable cause to believe that
his or her conduct was unlawful.</P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0">Our Memorandum and Articles provide for the indemnification of our directors against all losses
or liabilities incurred or sustained by a director as a director of our company in defending any proceedings, whether civil or criminal
and this indemnity only applies if he or she acted honestly and in good faith with a view to our best interests and, with respect to any
criminal action, he or she must have had no reasonable cause to believe his or her conduct was unlawful.</P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0">We may purchase and maintain insurance in relation to any person who is or was a director, or
who at the request of the company is or was serving as a director of, or in any other capacity is or was acting for another body corporate
or a partnership, joint venture, trust or other enterprise, against any liability asserted against the person and incurred by the person
in that capacity, whether or not we have or would have had the power to indemnify the person against the liability. We currently maintain
director and officer insurance.</P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0">Insofar as indemnification for liabilities arising under the Securities Act may be permitted
for directors, officers or persons controlling us under the foregoing provisions, we have been advised that, in the opinion of the SEC,
such indemnification is against public policy as expressed in the Securities Act and therefore is unenforceable.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0"><B>Item 7. Recent Sales of Unregistered Securities</B></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">The following sets forth information regarding all unregistered securities sold within the past
three years:</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pursuant to the Securities Purchase Agreement, on October 3, 2023, for each ordinary share and Pre-Funded
Warrant issued and sold in the Registered Direct Offering, we issued accompanying unregistered Series A Warrant, Series B Warrant and
Series C Warrant to a certain Selling Shareholder in the concurrent Private Placement to purchase up to 157,895 of our ordinary shares.
Each Series A Warrant is exercisable for one Series A Warrant Share at an exercise price of $38.00 per share, is immediately exercisable
and will expire 18 months from the date of issuance. Each Series B Warrant is exercisable for one Series B Warrant Share at an exercise
price of $45.20 per share, is immediately exercisable and will expire three years from the date of issuance. Each Series C Warrant is
exercisable for one Series C Warrant Share at an exercise price of $45.20 per share, is immediately exercisable and will expire five years
from the date of issuance.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pursuant to an engagement letter, dated as of August 26, 2023, between us and the Placement Agent, we
issued to designees of the Placement Agent unregistered warrants to purchase up to 7,896 Placement Agent Warrants, which represented 5.0%
of the aggregate number of ordinary shares and Pre-Funded Warrants sold in the Registered Direct Offering. The Placement Agent Warrants
have an exercise price equal to $47.50, or 125% of the offering price per share sold in the Registered Direct Offering, and will expire
five years from the commencement of the sales pursuant to the Registered Direct Offering and Private Placement.</TD></TR></TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pursuant to the Agreement and Plan of Merger and Reorganization with Tarus Therapeutics, Inc. (&ldquo;<B>Tarus</B>&rdquo;)
dated as of July 1, 2022, we issued to the former Tarus shareholders 121,300 of our ordinary shares, calculated on the basis of $18 million
divided by the 60-day volume weighted average price per share of our ordinary shares.</TD></TR></TABLE>
<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B></B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify"><B>&nbsp;</B></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0 0pt 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.5pt"></TD><TD STYLE="width: 18pt"><FONT STYLE="font-family: Symbol">&middot;</FONT></TD><TD STYLE="text-align: justify">Pursuant to the Share Exchange Agreement among us, our wholly-owned subsidiary SalvaRx Ltd. and each of
the minority shareholders of iOx Therapeutics Ltd. (&ldquo;<B>iOx</B>&rdquo;), dated as of July 18, 2022, we exchanged 53,500 of our ordinary
shares for the remaining minority interest of 21.68% of iOx.</TD></TR></TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">The securities described above were offered and sold without registration
under the Securities Act in reliance on the exemption provided by Section 4(a)(2) of the Securities Act and Rule 506 of Regulation D promulgated
thereunder.</P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0"><B>Item 8. Exhibits and Financial Statement Schedules</B></P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0">(a) The following documents are filed as part of this registration statement:</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<!-- Field: Page; Sequence: 47 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR>
    <TD STYLE="vertical-align: bottom; width: 9%; border-bottom: black 1pt solid"><B>Exhibit<BR>
Number</B></TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: top; width: 1%">&nbsp;</TD>
    <TD STYLE="vertical-align: bottom; width: 89%; border-bottom: black 1pt solid; text-align: center"><B>Description</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">2&loz;+</TD>
    <TD><FONT STYLE="color: #0000EE">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #0000EE">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004791/exh_21.htm">Agreement and Plan of Merger and Reorganization among Portage Biotech Inc., Portage Merger Sub 1, Inc., Portage Merger Sub 2, LLC, Tarus Therapeutics, Inc. and Shareholder Representative Services LLC dated as of July 1, 2022 - <B>Incorporated herein by reference </B>to Exhibit 2.1 to Form 6-K filed on July 8, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">3.1</TD>
    <TD><FONT STYLE="color: #0000EE">&nbsp;</FONT></TD>
    <TD><FONT STYLE="color: #0000EE">&nbsp;</FONT></TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000109543513000048/continucert2013.pdf">Certificate of Continuance -&nbsp;Incorporated herein by reference&nbsp;to Exhibit 3.1 to Form 6-K filed on August 1, 2013.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">3.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004510/exh_991.htm">Memorandum of Association and Articles of Association of Portage Biotech Inc. as filed in the British Virgin Island on June 21, 2022 &ndash; <B>Incorporated herein by reference</B> to Exhibit 99.1 to Form 6-K filed on June 23, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">3.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184322006193/exh_41.htm">Amended and Restated Memorandum of Association and Articles of Association of Portage Biotech Inc. as filed in the British Virgin Island on September 22, 2022 &ndash; <B>Incorporated herein by reference</B> to Exhibit 4.1 to Form 6-K filed on September 22, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">4.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184322005215/exh_21.htm">Description of Rights of Stock Registered under Section 12 of the Exchange Act &ndash; <B>Incorporated herein by reference </B>to Exhibit 2.1 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">4.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_41.htm">Form of Pre-Funded Ordinary Share Purchase Warrant, dated September 29, 2023 -&nbsp;Incorporated herein by reference&nbsp;to Exhibit 4.1 to Form 6-K filed on October 3, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">4.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_42.htm">Form of Series A Ordinary Share Purchase
    Warrant, dated September 29, 2023 - Incorporated herein by reference to Exhibit 4.2 to Form 6-K filed on October 3, 2023.</A> </TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">4.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_43.htm">Form of Series B Ordinary Share Purchase
Warrant, dated September 29, 2023 - Incorporated herein by reference to Exhibit 4.3 to Form 6-K filed on October 3, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">4.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_44.htm">Form of Series C Ordinary Share Purchase Warrant, dated September 29, 2023 - Incorporated herein by reference to Exhibit 4.4 to Form 6-K filed on October 3, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">4.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_45.htm">Form of Placement Agent Ordinary Share Purchase Warrant, dated September 29, 2023 - Incorporated herein by reference to Exhibit 4.5 to Form 6-K filed on October 3, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">5.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006549/exh_51.htm">Opinion of Forbes Hare LLP&ndash; <B>Incorporated herein by reference</B> to Exhibit 5.1 to Form F-1 filed on October 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000106299321001953/exhibit1-1.htm">Controlled Equity OfferingSM Sales Agreement by and between Portage Biotech Inc. and Cantor Fitzgerald &amp; Co., dated February 24, 2021 - <B>Incorporated herein by reference</B> to Exhibit 1.1 to Form F-3 filed on February 24, 2021.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000109543511000021/stockcompensation2011.htm">2011 Consultant Stock Compensation Plan -&nbsp;<B>Incorporated herein by reference</B>&nbsp;to Exhibit 10.1 to Form S-8 filed on April 21, 2011.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.3</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1095435/000109543513000084/stockcompensation2013.htm">2013 Stock Option Plan -&nbsp;<B>Incorporated herein by reference</B>&nbsp;to Exhibit 10 to Form S-8 filed on December 19, 2013.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.4</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="http://www.sec.gov/Archives/edgar/data/1095435/000109543515000009/optionplan.htm">Stock Option Plan -&nbsp;<B>Incorporated herein by reference</B>&nbsp;to Exhibit 10 to Form S-8 filed on March 17, 2015.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.5</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184321005284/exh_44.htm">Portage Biotech Inc. 2021 Equity Incentive Plan dated as of January 13, 2021 - <B>Incorporated herein by reference</B> to Exhibit 4(c)(iv).4 to Form 20-F filed on July 29, 2021.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.6</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323007378/exh_42.htm">Portage Biotech Inc. Amended and Restated 2021 Equity Incentive Plan - <B>Incorporated herein by reference</B> to Exhibit 4.2 to Form S-8 filed on December 1, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.7</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004791/exh_103.htm">Purchase Agreement dated as of July 6, 2022, by and between Portage Biotech Inc. and Lincoln Park Capital Fund, LLC - <B>Incorporated herein by reference</B> to Exhibit 10.3 to Form 6-K filed on July 8, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.8</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004791/exh_104.htm">Registration Rights Agreement dated as of July 6, 2022, by and between Portage Biotech Inc. and Lincoln Park Capital Fund, LLC - <B>Incorporated herein by reference</B> to Exhibit 10.4 to Form 6-K filed on July 8, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.9</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_105.htm">Services Agreement effective as of December 15, 2021, by and between Portage Development Services Inc. and Ian B. Walters, MD - <B>Incorporated herein by reference</B> to Exhibit 10.5 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.10</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_106.htm">Services Agreement effective as of December 1, 2021, by and between Portage Development Services Inc. and Allan Shaw - <B>Incorporated herein by reference</B> to Exhibit 10.6 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.11</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_107.htm">Services Agreement effective as of December 1, 2021, by and between Portage Development Services Inc. and Robert Kramer, PhD - <B>Incorporated herein by reference</B> to Exhibit 10.7 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  </TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 9%; text-align: center">10.12</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 89%"><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_108.htm">Services Agreement effective as of December 15, 2021, by and between Portage Development Services Inc. and Steven Innaimo - <B>Incorporated herein by reference</B> to Exhibit 10.8 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.13</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_109.htm">Services Agreement effective as of December 1, 2021, by and between Portage Development Services Inc. and Brian Wiley - <B>Incorporated herein by reference</B> to Exhibit 10.9 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.14</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_1010.htm">Form of Share Option Agreement dated as of January 13, 2021 - <B>Incorporated herein by reference</B> to Exhibit 10.10 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.15</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_1011.htm">Form of Share Option Agreement dated as of January 13, 2021 - <B>Incorporated herein by reference</B> to Exhibit 10.11 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.16</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_1012.htm">Form of Restricted Share Unit Award and Dividend Equivalent Rights Agreement dated as of January 13, 2021 - <B>Incorporated herein by reference</B> to Exhibit 10.12 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.17</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_1013.htm">Form of Share Option Agreement dated as of January 19, 2022 - <B>Incorporated herein by reference</B> to Exhibit 10.13 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.18</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_1014.htm">Form of Share Option Agreement dated as of January 19, 2022 - <B>Incorporated herein by reference</B> to Exhibit 10.14 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.19</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_1015.htm">Form of Restricted Share Unit Award and Dividend Equivalent Rights Agreement dated as of January 19, 2022 - <B>Incorporated herein by reference</B> to Exhibit 10.15 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.20</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184322005215/exh_1016.htm">Form of Share Option Agreement dated as of February 15, 2022 - <B>Incorporated herein by reference</B> to Exhibit 10.16 to Form 20-F filed on August 1, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184323004814/exh_424.htm">Services Agreement effective as of June 1, 2022, by and between Portage Development Services Inc. and Justin Fairchild - <B>Incorporated herein by reference</B> to Exhibit 4.24 to Form 20-F filed on July 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.22</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184323004814/exh_425.htm">Clinical Services Agreement effective as of March 1, 2023, by and between Fortrea Inc. (formerly Labcorp Drug Development Inc.) and Tarus Therapeutics LLC - <B>Incorporated herein by reference</B> to Exhibit 4.25 to Form 20-F filed on July 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.23</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184323004814/exh_426.htm">Form of Share Option Agreement dated as of March 30, 2023 - <B>Incorporated herein by reference </B>to Exhibit 4.26 to Form 20-F filed on July 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.24</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184323004814/exh_427.htm">Form of Share Option Agreement dated as of March 30, 2023 - <B>Incorporated herein by reference</B> to Exhibit 4.27 to Form 20-F filed on July 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.25</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184323004814/exh_428.htm">Form of Share Option Agreement dated as of March 30, 2023 - <B>Incorporated herein by reference</B> to Exhibit 4.28 to Form 20-F filed on July 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.26</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184323004814/exh_429.htm">Office Lease made as of March 31, 2023, by and between WALP 57-61, LLC and Portage Development Services, Inc. - <B>Incorporated herein by reference</B> to Exhibit 4.29 to Form 20-F filed on July 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.27</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324004800/exh_428.htm">First Amendment of Lease made as of February 20, 2024, by and between WALP 57-61, LLC and Portage Development Services, Inc.- <B>Incorporated herein by reference</B> to Exhibit 4.28 to Form 20-F filed on August 14, 2024.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.28&loz;+</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184323004814/exh_430.htm">License Agreement dated as of July 1, 2015, by and between iOx Therapeutics Ltd. and the Ludwig Institute for Cancer Research Ltd. - <B>Incorporated herein by reference</B> to Exhibit 4.30 to Form 20-F filed on July 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.29&loz;+</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/0001095435/000117184323004814/exh_431.htm">License Agreement dated as of October 29, 2019, by and between Tarus Therapeutics, Inc. and Impetis Biosciences Limited - <B>Incorporated herein by reference</B> to Exhibit 4.31 to Form 20-F filed on July 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">10.30&loz;+</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184322004885/exh_21.htm">Share Exchange Agreement dated as of July 18, 2022, by and among Portage Biotech Inc., SalvaRx Ltd., and each of the shareholders of iOx Therapeutics Ltd. - <B>Incorporated herein by reference</B> to Exhibit 2.1 to Form 6-K filed on July 19, 2022.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">10.31</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006015/exh_101.htm">Form of Securities Purchase Agreement, dated September 29, 2023, by and between Portage Biotech Inc. and the Purchaser signatory thereto &ndash; <B>Incorporated herein by reference</B> to Exhibit 10.1 to Form 6-K filed on October 3, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">21</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184324004800/exh_81.htm">List of Subsidiaries &ndash; <B>Incorporated herein by reference</B> to Exhibit 8.1 to Form 20-F filed on August 14, 2024.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">23.1*</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><U><A HREF="exh_231.htm">Consent of Marcum LLP.</A></U></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">23.2</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006549/exh_51.htm">Consent of Forbes Hare LLP (included in Exhibit 5.1) - <B>Incorporated herein by reference</B> to Exhibit 24.1 to Form F-1 filed on October 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="text-align: center">24.1</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006549/ff1_102723.htm#poa">Power of Attorney - <B>Incorporated herein by reference</B> to Exhibit 24.1 to Form F-1 filed on October 31, 2023.</A></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">107</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><A HREF="https://www.sec.gov/Archives/edgar/data/1095435/000117184323006549/exh_107.htm">Filing Fee Table - <B>Incorporated herein by reference</B> to Exhibit 107 to Form F-1 filed on October 31, 2023.</A></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">_________________</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">* Filed herewith.</P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&loz; Schedules have been omitted pursuant to <FONT STYLE="background-color: white">Item
601(a)(5) of Regulation S-K</FONT>. The registrant undertakes to furnish supplemental copies of any of the omitted schedules upon request
by the SEC.</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">+ Portions of this exhibit <FONT STYLE="background-color: white">have been omitted pursuant
to Item 601(b)(10)(iv) of Regulation S-K</FONT>.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt"></P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0"><B>Item 9. Undertakings</B></P>

<P STYLE="text-align: justify; font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0"></TD><TD STYLE="text-align: justify; width: 0.5in">(a)</TD><TD STYLE="text-align: justify">The undersigned registrant hereby undertakes:</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">(1)</TD><TD STYLE="text-align: justify">To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 99pt"></TD><TD STYLE="text-align: justify; width: 18pt">(i)</TD><TD STYLE="text-align: justify">To include any prospectus required by section 10(a)(3) of the Securities Act of 1933;</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>



<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 99pt"></TD><TD STYLE="width: 18pt">(ii)</TD><TD STYLE="text-align: justify">To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the most recent
post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth
in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered (if the total dollar
value of securities offered would not exceed that which was registered) and any deviation from the low or high end of the estimated maximum
offering range may be reflected in the form of prospectus filed with the SEC pursuant to Rule 424(b) if, in the aggregate, the changes
in volume and price represent no more than a 20% change in the maximum aggregate offering price set forth in the &ldquo;Calculation of
Filing Fee Tables&rdquo; or &ldquo;Calculation of Registration Fee&rdquo; table, as applicable, in the effective registration statement;
and</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 99pt"></TD><TD STYLE="text-align: justify; width: 18pt">(iii)</TD><TD STYLE="text-align: justify">To include any material information with respect to the plan of distribution not previously disclosed in the registration statement
or any material change to such information in the registration statement.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">(2)</TD><TD STYLE="text-align: justify">That, for the purpose of determining any liability under the Securities Act of 1933, each such post-effective amendment shall be deemed
to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall
be deemed to be the initial bona fide offering thereof.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">(3)</TD><TD STYLE="text-align: justify">To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the
termination of the offering.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">(4)</TD><TD STYLE="text-align: justify">To file a post-effective amendment to the registration statement to include any financial statements required by Item 8.A of Form
20-F at the start of any delayed offering or throughout a continuous offering. Financial statements and information otherwise required
by Section 10(a)(3) of the Securities Act need not be furnished, provided that the registrant includes in the prospectus, by means of
a post-effective amendment, financial statements required pursuant to this paragraph (a)(4) and other information necessary to ensure
that all other information in the prospectus is at least as current as the date of those financial statements.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">(5)</TD><TD STYLE="text-align: justify">That, for the purpose of determining liability under the Securities Act of 1933 to any purchaser:</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 99pt"></TD><TD STYLE="text-align: justify; width: 18pt">(i)</TD><TD STYLE="text-align: justify">Each prospectus filed by the registrant pursuant to Rule 424(b)(3) shall be deemed to be part of the registration statement as of
the date the filed prospectus was deemed part of and included in the registration statement; and</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 99pt"></TD><TD STYLE="text-align: justify; width: 18pt">(ii)</TD><TD STYLE="text-align: justify">Each prospectus required to be filed pursuant to Rule 424(b)(2), (b)(5) or (b)(7) as part of a registration statement in reliance
on Rule 430B relating to an offering made pursuant to Rule 415(a)(1)(i), (vii) or (x) for the purpose of providing the information required
by Section 10(a) of the Securities Act of 1933 shall be deemed to be part of and included in the registration statement as of the earlier
of the date such form of prospectus is first used after effectiveness or the date of the first contract of sale of securities in the offering
described in the prospectus. As provided in Rule 430B, for liability purposes of the issuer and any person that is at that date an underwriter,
such date shall be deemed to be a new effective date of the registration statement relating to the securities in the registration statement
to which the prospectus relates, and the offering of such securities at that time shall be deemed to be the initial bona fide offering
thereof. Provided, however, that no statement made in a registration statement or prospectus that is part of the registration statement
or made in a document incorporated or deemed incorporated by reference into the registration statement or prospectus that is part of the
registration statement will, as to a purchaser with a time of contract of sale prior to such effective date, supersede or modify any statement
that was made in the registration statement or prospectus that was part of the registration statement or made in any such document immediately
prior to such effective date.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt"></P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in">(b)</TD><TD STYLE="text-align: justify">Insofar as indemnification for liabilities arising under the Securities Act of 1933 may be permitted to directors, officers and controlling
persons of the registrant pursuant to the foregoing provisions, or otherwise, the registrant has been advised that in the opinion of the
Securities and Exchange Commission such indemnification is against public policy as expressed in the Securities Act of 1933 and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the registrant of expenses
incurred or paid by a director, officer or controlling person of the registrant in the successful defense of any action, suit or proceeding)
is asserted by such director, officer or controlling person in connection with the securities being registered, the registrant will, unless
in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the
question whether such indemnification by it is against public policy as expressed in the Securities Act of 1933 and will be governed by
the final adjudication of such issue.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.25in"></TD><TD STYLE="text-align: justify; width: 0.25in">(c)</TD><TD STYLE="text-align: justify">The undersigned registrant hereby undertakes that:</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">(1)</TD><TD STYLE="text-align: justify">For purposes of determining any liability under the Securities Act of 1933, the information omitted from the form of prospectus filed
as part of this registration statement in reliance upon Rule 430A and contained in a form of prospectus filed by the registrant pursuant
to Rule 424(b)(1) or (4) or 497(h) under the Securities Act of 1933 shall be deemed to be part of this registration statement as of the
time it was declared effective.</TD></TR></TABLE>

<P STYLE="text-align: justify; margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="text-align: justify; width: 0.75in"></TD><TD STYLE="text-align: justify; width: 0.25in">(2)</TD><TD STYLE="text-align: justify">For the purpose of determining any liability under the Securities Act of 1933, each post-effective amendment that contains a form
of prospectus shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such
securities at that time shall be deemed to be the initial bona fide offering thereof.</TD></TR></TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 4pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: center"><B>SIGNATURES </B></P>

<P STYLE="font-size: 10pt; text-indent: 24pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="text-align: justify; font-size: 10pt; text-indent: 24pt; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable
grounds to believe that it meets all of the requirements for filing on Form F-1 and has duly caused this registration statement to be
signed on its behalf by the undersigned, thereunto duly authorized, in the city of Westport, State of Connecticut, on August 22, 2024.</P>

<P STYLE="font-size: 10pt; text-indent: 24pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>PORTAGE BIOTECH INC.</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%"><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid; width: 35%"><FONT STYLE="font-size: 10pt">/s/ Ian Walters, MD, MBA&#9;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Ian Walters, MD, MBA&#9;</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Chief Executive Officer </FONT></TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"></P>



<P STYLE="font-size: 10pt; text-indent: 24pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-indent: 0.25in; margin: 0pt 0">Pursuant to the requirements of the Securities Act of 1933, this registration
statement has been signed by the following persons in the capacities and on the date indicated.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 29%"><B>Name</B></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 49%"><B>Title</B></TD>
    <TD STYLE="text-align: center; width: 1%">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1pt solid; text-align: center; width: 20%"><B>Date</B></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD STYLE="text-align: center">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid">/s/ Ian Walters, MD, MBA </TD>
    <TD>&nbsp;</TD>
    <TD>Chief Executive Officer, Chairman of the Board and Director</TD>
    <TD>&nbsp;</TD>
    <TD>August 22, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Ian Walters, MD, MBA </TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Executive Officer)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid">/s/ Allan Shaw</TD>
    <TD>&nbsp;</TD>
    <TD>Chief Financial Officer</TD>
    <TD>&nbsp;</TD>
    <TD>August 22, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Allan Shaw</TD>
    <TD>&nbsp;</TD>
    <TD>(Principal Financial and Accounting Officer)</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: #212529; background-color: white">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD>August 22, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Gregory Bailey, MD</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: #212529; background-color: white">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD>August 22, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Jim Mellon</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: black 1pt solid"><FONT STYLE="color: #212529; background-color: white">*</FONT></TD>
    <TD>&nbsp;</TD>
    <TD>Director</TD>
    <TD>&nbsp;</TD>
    <TD>August 22, 2024</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>Steven Mintz </TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 21%">*By:</TD>
    <TD STYLE="width: 79%; border-bottom: black 1pt solid">/s/ Ian Walters, MD, MBA </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name: </TD>
    <TD>Ian Walters, MD, attorney-in-fact </TD></TR>
  </TABLE>
<P STYLE="font-size: 10pt; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; text-indent: 0.5in; margin: 0pt 0"><B>SIGNATURE OF AUTHORIZED REPRESENTATIVE IN THE UNITED
STATES</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; text-align: justify; text-indent: 0.5in; margin: 0pt 0">Pursuant to the requirements of the Securities Act
of 1933, as amended, the undersigned, the duly authorized representative in the United States of the Registrant, has signed this Registration
Statement on August 22, 2024.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
  <TR STYLE="vertical-align: top">
    <TD>By:</TD>
    <TD STYLE="border-bottom: black 1pt solid">/s/ Ian Walters, MD, MBA </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Name: </TD>
    <TD>Ian Walters, MD, MBA </TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>Title:</TD>
    <TD>Chief Executive Officer </TD></TR>
  </TABLE>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>















</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>exh_231.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font-size: 10pt; text-align: right; margin: 0pt 0"><B>Exhibit 23.1</B></P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font-size: 10pt; text-align: center; margin: 0pt 0"><FONT STYLE="text-transform: uppercase"><U>Independent Registered Public
Accounting Firm&rsquo;s Consent</U></FONT></P>

<P STYLE="font-size: 10pt; text-align: justify; margin: 0pt 0">&nbsp;</P>

<P STYLE="margin: 0pt 0; font-size: 10pt; text-align: justify">We consent to the incorporation by reference in this Registration Statement
of Portage Biotech Inc. on Post-Effective Amendment No. 1 to Form F-1 (File No. 333-275229) of our report dated August 14, 2024, which
includes an explanatory paragraph as to the Company&rsquo;s ability to continue as a going concern, with respect to our audits of the
consolidated financial statements of Portage Biotech Inc. as of March 31, 2024 and 2023 and for each of the three years in the period
ended March 31, 2024, appearing in the Annual Report on Form 20-F of Portage Biotech Inc. for the year ended March 31, 2024. We also consent
to the reference to our firm under the heading &ldquo;Experts&rdquo; in the Prospectus, which is part of this Registration Statement.</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">/s/ Marcum <FONT STYLE="font-variant: small-caps">LLP</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">Marcum <FONT STYLE="font-variant: small-caps">LLP</FONT></P>

<P STYLE="font-size: 10pt; margin: 0pt 0">New York, NY</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">August 22, 2024</P>

<P STYLE="font-size: 10pt; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>logo.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !@ .$# 2(  A$! Q$!_\0
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MEC\5ZMX=81^(; O!T^WV0+)]67J*[.D90RD$9!Z@UU_67/2LN;\_O_SN>?\
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M&P?49J6B@-]Q%4*H"@ #H!2TC,$4LQ"@=2:BAO+>X;;%/'(WHC@F@":BBB@
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M4I:72=2DWQS+CD*>QKVVHKK_ (]9O]QOY4 >0_LSZU?Z[X:UJXU"::6;^T'
M29RQC']W\*ZGXL?$Q/AWH\7V:W^WZU>MY5E9KU=NF3[#(KD?V8?^0#XC_P"P
MK+_.H/*'B7]IQEO )(='T\/;QMT#G^(?G0!'IOP/U[QQMU/QSXDOO/F&X:=8
MR>7'$#_"<>E6[C]GF7P\RWWA#Q+J.FZC%\R1W,IDA?V8>]>T44 >*?"7QQXH
M\0?$[Q%IGB _9C9P(#9+@HCYP64^AZ_C7IGCCQE8> _#=UK&H-^ZA'RQK]Z1
MCT4>Y->8^ ?^3B/'/_7&/^E9?[3=[?7'B+P9I-G8MJ;/<&Y%B&VB=E/"D^E
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>NGPK;VEN@1$7T_QJ_110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>pipe.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pipe.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %\ M\# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZM1?0)!<(YEMS@"9 #\T9R/F''(YK1H **** "BJM]JEGIIMA>7<%H;F9;>
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MN-+GFDFU)H)!+&OEM&JP*71"V'D/& 14[?"2\/QD'B/[;!_PB^[^U#I>#O\
M[5$/V<38QMV^3WSG> ?>@#CYOVAI]2DUN:P\7^ =&73;J:S@TO7;L1W6H-"Q
M1W)^T+]F5F5MFY)#C!/6MCX;>+K;Q[\83XCLT:*VU3P/I=TD<GWDW75X2I]2
M#D9]JT=,\&>// D.LZ/X5ET&YT6\O+B\L+C5)YDGTTSR&21/*6-EG4.[LN7C
M/."36[H'@75=+^)$WB&]U&/4H9/#MGI+W#J$GFGBFGD>5D50BJPE7[IZY&
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MN8]L,HW.& 887(0 ,!4>A_!/Q1HNG0:@FIZ2/%6G^(+O6K1HXY%LIH[F/9+
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M+74_ T,FOW%Q',4DU$E699F?A90?X3@@<8KZGH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BD.<' R:R/[0UG_ * \/_@:/_B* -BBL?\
MM#6?^@/#_P"!H_\ B*/[0UG_ * \/_@:/_B* -BBL?\ M#6?^@/#_P"!H_\
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M?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\
M:&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\
M$4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T
M?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_
M] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?V
MAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4
M ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'
M_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_
M $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%
M8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #
M1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X
M?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\
M:&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\
M$4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T
M?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_
M] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?V
MAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4
M ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'
M_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_
M $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%
M8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #
M1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X
M?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\
M:&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\
M$4?VAK/_ $!X?_ T?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T
M?_$4 ;%%8_\ :&L_] >'_P #1_\ $4?VAK/_ $!X?_ T?_$4 ;%%9]C=:A-,
M5NK".VCQG>MQYASZ8VBM"@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKD/BUX?O?%7P_U32].@
M2YO+@P[(I-NU@)D9L[B 1@'C(SC% '7T5X_8_#O5/ &L>'+JQLI/$%O;7.H7
M%Q%IJ0VJ0>>D:JD4<LP 0%3P&/>L^X\%^+]:^)A\3:CH-M/I%Q/_ &;-I=U=
MQR.=/P,%HN8R!(/-QO)R<;>] 'N%%>#:-\#YY/#/@?3;O2+?3G@O+J;5I(8;
M25@"DPB+"1723[R 95MH/;&0_P 9?"W6)M4U:*PT+^TI98;2'1=:6ZB@_LD1
M1JA^0%2GS*7Q$N#NQ@=* /=J*\&U+X4>(IO%E]JHT^UFCEUF2;[1"L<=\\1M
M516\TOCR3)G=%@,.2,YK+\#_  A\8:1JO@TZC;?Z#H%Q T*?:(VV+-#(]T3\
MW\,QC3C.>HX% SZ-HHJMJ6FV>L64MG?VD%]:2@"2WN8UDC?!R,J00>0#^% B
MS17SM:_!F^L_"O@.WN/#+/-91W1U6/3X]/DE,CA1&S"XS%(<#KR0!VKHT\!W
M]OXMFNI_!W]LR27MK/8ZM+J$=N=/MU2,&(JC94H5<XC!5MWH*!GLU%>&7'PO
M\3-J#7(%Q+"VK:W<"S:2W$4<=Q#<+#(I #Y<R(,%CC/(7%8EI\(_&]K:-:31
M_;[.#2K.WCC:Z2-YHUG66:R9@W&,R*&^Z5VC- 'T=17AEOX#UZQ\Z[L/#$NF
MZ8NN:??VWA^&[@9XTB#>=(O[P1J7)7Y0W\-,\:>!_$/BC6-<OU\+3M?ZBMO_
M &3J-Q?PI)HQ10K [9#CY@TG[O=G=@X.10(]VHKP^7X>^((_'8O)_#UKK$KZ
MRMR^O7$V2+,[1Y:@3(Z%%W#9L=&R,C YZOX:_#D^%M<UJ\NHI!'#.]GHT<D@
M=;>Q.)-J8)P#([CYN<1J.E 'HM%%% !1110 4444 %%%% !1110 45XY\3O"
M_C;7O'=GK>BV$+6WA]8GL4FOA&;J1F#3[4 Q@H!'\[)W()!K-L?A[X@C^(6K
M:HGA]X;2^%\99I[V$.?-C/EB.:,^8,M@;71ECYVDX% 'NM%?-=G\)?$T?A^?
M3Y/#C)8_;]/G,*M8FYD2(.)?E+?9WP"/F< N3E@>W;K\*+2Y\1>!+P>%K=+.
MR6[&H?;K6R6493]SYBP#RV^;)&P$#.>#F@#UVBBB@ HHHH **** "BBB@ HH
MHH ***^<[SX2^-/[+M'L(/LE]:Z->VIA:>,I<&:ZD)@;#=XI-P;H&5<D4 ?1
ME%> #X8ZY_;$CKX9V:D]SI4MOK_VF!?LD<,%NLZ\/YC9,<B[=NTYSFF0_#'6
M[6TT_P#M/P@/$T<>GS6\5DU_'$+2X:[FD\TDN -R.GS)EAMQB@9]!45XCXH\
M'>,]6\<VOB"#18'L](^SVD%C+J*LUS;,I6Z4*RE7#>9@-(R'$0.TDXI^E_"6
MYTEI);3P_:6<W_"8+?1O L*,-/5P5P0>%')"=1Z4"/:Z*\#\-_#+Q%8WFF?\
M2/\ L_4;:*[75=;^VQR?VOOC<*-H;<<L5;]X!MQQ6M\'?ASXF\%^(=/.K#SM
M-@T!+>*1I49X)F>-Y+<X/(5Q)AAD;2!GB@#V:BBB@ HHHH **** "BBB@ HH
MHH **** "BN(^+WANZ\4^%8K.SL9=0D6[BF,,4D*G:I)R4F'ERCIF-R ?48K
MS^/X3ZA>Z3X .J>%K"XN-,NYA?0@0NWV7]Z8T;>Q#?,P.Q6*@GC Z 'N]%?/
M=E\/?B*B^(YGM8;:?Q19S-=>3J()M[@2%HP?E&T&-C#\C/T!) IMY\-=>O-/
MU*UMO!<.CZ5->6$XLK66!IY%CE)D^62>2!R%S\S*N\GYE(XH&?0U%87@?2TT
M7PM8V<=E/IRQ!\6US%;1R+EV/*VW[H9SGY/7GG-;M @HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M232/^@I9?^!"?XU:_L^U_P"?:'_OV/\ "J^H:?:BPN2+:$'RF_Y9CT- #?\
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M_P"@I9?^!"?XT?\ "2:1_P!!2R_\"$_QJU_9]K_S[0_]^Q_A1_9]K_S[0_\
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M4/G/_P ^\GYK_C1YS_\ /O)^:_XT 345#YS_ //O)^:_XT><_P#S[R?FO^-
M$U5]/_Y!]M_UR7^0IWG/_P ^\GYK_C5?3YG%A;?N)#^Z7G*^@]Z +U%0^<__
M #[R?FO^-'G/_P ^\GYK_C0!-14/G/\ \^\GYK_C1YS_ //O)^:_XT 345#Y
MS_\ /O)^:_XT><__ #[R?FO^- $U%0^<_P#S[R?FO^-'G/\ \^\GYK_C0!-1
M4/G/_P ^\GYK_C1YS_\ /O)^:_XT 345#YS_ //O)^:_XT><_P#S[R?FO^-
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M/S7_ !H\Y_\ GWD_-?\ &@":BH?.?_GWD_-?\:/.?_GWD_-?\: )J*A\Y_\
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MJ65&\V9"#A2<C(]ZJ1_&SPB]GIMP=0G#:A;PW-O ME/+*ZRLZQ@*B-EBT;C
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M@$7R*))I2!#Y8PY%4-/_ &;M TB.]_L_6-:LI[R*:VEN(Y(&<PS)&LL0W0D
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M/B:70+/4H88(I9+Q(U#S1I(J;7#9V.I!Z?AUK[7N+>*ZC,<J!T]#7)7GP?\
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M\E_PJ6B@"+R7_P">\GY+_A1Y+_\ />3\E_PJ6B@"+R7_ .>\GY+_ (4>2_\
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MQX\HRA)QDK-%WR7_ .>\GY+_ (4>2_\ SWD_)?\ "J7_  D-E_ST;_ODT?\
M"0V7_/1O^^35V9)=\E_^>\GY+_A1Y+_\]Y/R7_"J7_"0V7_/1O\ ODT?\)#9
M?\]&_P"^319@7?)?_GO)^2_X4>2__/>3\E_PJE_PD-E_ST;_ +Y-'_"0V7_/
M1O\ ODT68%WR7_Y[R?DO^%'DO_SWD_)?\*I?\)#9?\]&_P"^31_PD-E_ST;_
M +Y-%F!=\E_^>\GY+_A1Y+_\]Y/R7_"J7_"0V7_/1O\ ODT?\)#9?\]&_P"^
M319@7?)?_GO)^2_X4>2__/>3\E_PJE_PD-E_ST;_ +Y-'_"0V7_/1O\ ODT6
M8%WR7_Y[R?DO^%'DO_SWD_)?\*I?\)#9?\]&_P"^30/$%B3_ *TC_@)HLP+O
MDO\ \]Y/R7_"CR7_ .>\GY+_ (4L%Q'<QAXG#KZBI*0$:1LK9,C/[,!_05)1
M10 4444 %<Q\1_$=WX5\)RZA8^6+G[5:6ZM+;27(42W,43-Y4;!Y"%D)"J<D
M@"NGJ&ZLX+Z-8[B&.XC5TE"RH& =&#HV#W5E5@>Q /:@#R?0_B!XTU[7O["Q
MI>D7 AGO(M1U/2[B(7ENC(BE+1IUDC(9FW%W) 53M^<8PK[X\Z])IMK>V<-C
M TFFV=PML=.N+N*YN)KF>#;]J21([>-C"FQY1@[\\XQ7L^O>%=%\50Q1:UH]
MAK$43%HTO[5)U0D8) <'!Q4DWA[2KFWG@FTRSE@N+=;2:-X$*R0KNVQ,".4&
M]\*>!N/J: .,L?%7B&S\7^(;?5KRQN-&TE;>3RM-T2YDNY!-OV@;)I"=I R1
M&<C)PHY%#P?\3-<U[X@2:==VEM%X?N&OX[&X^SO'+(UM+&A&3(6R,R!@\46"
MHVEQ7I<=C;PW4]S';Q1W,X42S*@#R!<[0QZG&3C/3)JI:^&](L=6N=4MM+LK
M?4[D;9[V*W19I1QPS@;F' ZGL* -*BBB@ K U[Q/9^"_ ]WKNH-ML].L3<R8
MZD*F=H]R>![D5OUGII]KJ>CVT%Y;0W<&V*3RYXPZ[E*LK8/<,H8'L0#VH \@
MT?XV:OX@\"M=VU]X>3Q%:7DEC<P6Z27J7,QC\R".VCCE!?>K+EB^%*2=E.W2
MA^.7E?%:Q\*WQTVVC>."RNHA.#<1:E+$TP1?FYB"JJ;MO+RH,CH>_P!9\ ^&
M/$=Y]KU;PYI.J76 //O+&*9\ $ ;F4G@$_F:MQ^%]&AL?L<>DV,=GYRW/V=;
M9!'YJL&63;C&X,JD-U! /:@#QWP;\;/$7B#3@9%T^YO;C3=/FA4Z9<:>(KJ[
MD"(FR:4M/$!O?S(\+B)N?31\/?'A?$WBSQ3I%K>:'%';P7$FDS7%QM'^C-Y=
MPUSAB57=\ZX"[HP3VW5ZC'X8T>*XL)TTFQ2>PC$-G(ML@:VC P$C./D7'&!@
M8J"\\%^'M0TRVTVZT'3+G3K5#'!:36<;Q1*5VE40KA05)& .AQ0!Y-K/Q=\7
MZ;8P2I':2":UU*\M)X_#UY-]OBM_LPB80I,6MU=II!OD)!"HW ;%7(/C)K-[
MXJL+2W-BUI=ZC96<=NNG7#K)'-:0W$CB_P#,$.Y5DD*Q[=S!!@?-FO0)?A?X
M-GM8;:3PCH4EM"SM%"VFPE(R^W>5&W +;$SCKM7/05KCP[I2P^4-,LQ%YT=Q
ML^SIM\V,((WQC[RB.,*>HV+CH* /.O%GQNMO#?Q7TOPPUQIZ6):""_,T@6X6
M:YWB#RP6&5!1=_!P)T.1@YQ+/X[:UXCCT%+31K73)]1?3;M U\9@]K//+$ZL
M3"-KAHNP/#9R",5[#-X?TNY@O(9M-M)8;V0374;P*5GD 4!W!'S, B#)YPB^
M@JFW@?PX\"0-H&EM#'''"D9LH]JHCET4#;P%8E@.@))'- 'G.B?'J[\17]KI
MVG^'X)=0OS"UEYE]-';R120W,NYI6MASMM6QY:R(VX;7(#$58_VCI)/"J>(C
MX;4:<T83:+XF;[3_ &;]OV;?*QY6WY/,SG/S;-O-=MK7PA\,:KICV5KIEGHJ
M23)/(VGZ?:_O60.%#I)$Z.!YCD;E."<C!J]I?PT\,:38V=LFAV$[6U@FF+<7
M-M'),]NL8C$;N5RP*#!!X(H \RU+]H;5[/7(=/7PW;O<*&,MI#=/,9-Z6;PE
M'$8(.+IMR"-R2@";B1GL_A[X^U'QMXDO=]M!;:6NE6MPL2RN9(KAKB[BE4AX
MD;K 00V"I0?+EB%Z2\\">&M0:5KKP]I5RTJ>7(TUE$Y==JKM.5Y&V-!CT11V
M%6M/\,Z/I,T,UCI5C92P0?98I+>V2-HX=V[RU('";N=HXSS0!IT444 %%%%
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M_OD4 2T5%]EA_P">,?\ WR*/LL/_ #QC_P"^10!+147V6'_GC'_WR*/LL/\
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M#8/6>&_#'BC0_BQ>2*VIS^%61D1M0U)[B-5\J+;LW7#,6WJ^=\0(RQ\QA@4
M>J4444 %%%% !1110 57U#_D'W/_ %R;^1JQ5?4/^0?<_P#7)OY&@#F/B=\0
M(OA[X?\ MIC6XO)G\JW@8X#-C))]@/Z5\^K\5/B%XHNI387=Y,4^8PZ?:@A
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M_P#Y!]M_UR7^0K-_X2*;_H!ZG_WS%_\ '*BM-=N(;6&-M$U+<B*IPL78?[]
M&_16+_PD4W_0#U/_ +YB_P#CE'_"13?] /4_^^8O_CE &U16+_PD4W_0#U/_
M +YB_P#CE'_"13?] /4_^^8O_CE &U16+_PD4W_0#U/_ +YB_P#CE'_"13?]
M /4_^^8O_CE &U16+_PD4W_0#U/_ +YB_P#CE'_"13?] /4_^^8O_CE &U16
M+_PD4W_0#U/_ +YB_P#CE'_"13?] /4_^^8O_CE &U16+_PD4W_0#U/_ +YB
M_P#CE'_"13?] /4_^^8O_CE &U16+_PD4W_0#U/_ +YB_P#CE'_"13?] /4_
M^^8O_CE &U16+_PD4W_0#U/_ +YB_P#CE'_"13?] /4_^^8O_CE &U5>3_D(
M0_\ 7*3^:5F_\)%-_P! /4_^^8O_ (Y43:[<-=1R?V)J6U493\L7<K_M^U &
M_16+_P )%-_T ]3_ .^8O_CE'_"13?\ 0#U/_OF+_P".4 ;5%8O_  D4W_0#
MU/\ [YB_^.4?\)%-_P! /4_^^8O_ (Y0!M45B_\ "13?] /4_P#OF+_XY1_P
MD4W_ $ ]3_[YB_\ CE &U16+_P )%-_T ]3_ .^8O_CE'_"13?\ 0#U/_OF+
M_P".4 ;5%8O_  D4W_0#U/\ [YB_^.4?\)%-_P! /4_^^8O_ (Y0!M45B_\
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MN^_9_P#"%Y<-*MK-;;B25BF8+^ [5U__  D4W_0#U/\ [YB_^.4?\)%-_P!
M/4_^^8O_ (Y7G8S+L'F"2Q=&-2VW,D[>ESLP^,Q.$;>'J.%^S:.(_P"&=?"?
M]VZ_[_&C_AG7PG_=NO\ O\:[?_A(IO\ H!ZG_P!\Q?\ QRC_ (2*;_H!ZG_W
MS%_\<KS/]6LE_P"@.G_X"O\ ([O[:S/_ *")_P#@3.(_X9U\)_W;K_O\:/\
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M;$_X1:#_ )ZR?I1_PBT'_/63]*7_ (2*;_H!ZG_WS%_\<H_X2*;_ * >I_\
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M^$6@_P">LGZ4O_"13?\ 0#U/_OF+_P".4?\ "13?] /4_P#OF+_XY1S,!/\
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MV.@W8    UJ* "BBB@ HHHH **** "BBB@ HHHH **** "LO7?#.F^)?[/\
M[2MOM/\ 9]Y'?VW[QE\N>/.Q_E(SC)X.1ZBM2B@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>pipe2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 pipe2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '' MX# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7 ZL?#
M<GC754\1/986TMC NI.!'UEW% _R[NF2.>GM7?54ATV&'4;J]7<9KA(T<$\8
M3=MQ_P!]']* .#A:TD73?^$F8?V$T<XM!J9_<L1.WE>:7ZMY/EE=_)^?^(&F
MM:1ZE)9VMI+*N@OK2BU,+E5,8M7,B1D?\LBP8#' RP7  KTFB@#A&T;PUIOQ
M ?[9I^EVLDME9KIYF@C3=*DD^1$2/O &+A>>5]JP]670E\+W\E\T(\7['\XR
M'%X)@>0F#N$>.F/E*8/0FO5Z3W[T <-=R: -:U5?$SVRWJRYM/MC8;R-BD-;
MYYSNSDI\VX?[M8$:&\M-!?6-2L;32CH=H86U>#S8GF(/FG+2*GF8\O[X8X)*
M_P =>CZSHHUI$BEO+J"UZ2V]NRHLPX^5FV[@/]UAD$YJ_'&D,:1QHL<: *JJ
M,  = !Z4 9WAG3(](T6WMH+V74+< O%-*RM\C'("D#&T X7T&!6I110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1A83,C 8^4G>!SFN"L?A'\1_B-JEJEQI^I^$-3U*3Q%->W#64BP*T[JXA,A
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M E0"1UH [BBN!MOC!:7NGS:A;>'?$%SIJPR7$-[%9J8KF-#\Q0[\CC)&\+N
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M444 %%%% !1110 4444 %%%% !1110 5SOBS3]&\8^'KW1;Z_C2UNU"2&&9
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M6AQY"^K^U3_V#IG_ $#K3_OPO^% ' 67PK\.V3:E,/$VIO>7T"VSWAOXEG5
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M/[7L?^?VW_[^K_C47]A:7_T#K/\ [\)_A1_86E_] ZS_ ._"?X4 2_VO8_\
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M,E:78B_3<PS[ UW=>7_'KX<7/Q6^#?B#P]8E1J,C&>UWG"F6.;>%)_VL%?\
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M&_\ P C_ /B:]%HH^LU_YW][#ZEA?^?4?N7^1YU_PS]\.O\ H0O#?_@!'_\
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MHH BW3?\\U_[[_\ K4;IO^>:_P#??_UJEHH BW3?\\U_[[_^M1NF_P">:_\
M??\ ]:I:CGN(K5 \TJ0H65 TC!069@JCGN20 .Y(% ";IO\ GFO_ 'W_ /6H
MW3?\\U_[[_\ K5+10!%NF_YYK_WW_P#6HW3?\\U_[[_^M69<>+]&M->AT2;4
M8(]4E7<ELS?,<]!GH">P)R>U;% $6Z;_ )YK_P!]_P#UJ-TW_/-?^^__ *U2
MT4 5UN)6F>/RERJAOO\ J3[>U/W3?\\U_P"^_P#ZU,C_ .0A-_URC_F]6* (
MMTW_ #S7_OO_ .M1NF_YYK_WW_\ 6J6B@"+=-_SS7_OO_P"M1NF_YYK_ -]_
M_6J6B@"+=-_SS7_OO_ZU&Z;_ )YK_P!]_P#UJEHH BW3?\\U_P"^_P#ZU&Z;
M_GFO_??_ -:I:* (MTW_ #S7_OO_ .M1NF_YYK_WW_\ 6J6B@"+=-_SS7_OO
M_P"M1NF_YYK_ -]__6J6B@"+=-_SS7_OO_ZU&Z;_ )YK_P!]_P#UJEHH BW3
M?\\U_P"^_P#ZU&Z;_GFO_??_ -:I:* (MTW_ #S7_OO_ .M3(;B692PB4 ,R
M_?\ 0D>GM5BJ45S%9V$]Q/(L4$33/)(YP%4,Q))] * V+&Z;_GFO_??_ -:C
M=-_SS7_OO_ZU?''Q&_X*$1Z;K-Q9>#O#\.HVD+E!J.HRL%FP<96-<';Z$MGV
M%<8?^"B/C7MX;T#_ +YG_P#CE?0T\AQ]2*ER6OW:/CJO%F4TIN'M&[=DVC[Z
MW3?\\U_[[_\ K4;IO^>:_P#??_UJ^!?^'B/C;_H7- _[YG_^.4?\/$?&W_0N
M:!_WS/\ _'*T_P!7L?\ RK[T9?ZX93_._P#P%GWUNF_YYK_WW_\ 6HW3?\\U
M_P"^_P#ZU? O_#Q'QM_T+F@?]\S_ /QRC_AXCXV_Z%S0/^^9_P#XY1_J]C_Y
M5]Z#_7#*?YW_ . L^^MTW_/-?^^__K4;IO\ GFO_ 'W_ /6KX%_X>(^-O^A<
MT#_OF?\ ^.4?\/$?&W_0N:!_WS/_ /'*/]7L?_*OO0?ZX93_ #O_ ,!9]];I
MO^>:_P#??_UJ-TW_ #S7_OO_ .M7P+_P\1\;?]"YH'_?,_\ \<H_X>(^-O\
MH7- _P"^9_\ XY1_J]C_ .5?>@_UPRG^=_\ @+/OK=-_SS7_ +[_ /K4;IO^
M>:_]]_\ UJ^!?^'B/C;_ *%S0/\ OF?_ ..5Z7\(OVZX/'&N6VB>(=(M]$O;
MIO+@NH9&>!W/16SRF>W)'TK&MD>.HP<Y0NEV:.K#\4Y5BJJI1J6;VNFOQ/J_
M=-_SS7_OO_ZU&Z;_ )YK_P!]_P#UJYW_ (2BY_YY1?D?\:/^$HN?^>47Y'_&
MO"Y6?6'1;IO^>:_]]_\ UJ-TW_/-?^^__K5SO_"47/\ SRB_(_XT?\)1<_\
M/*+\C_C1RL#HMTW_ #S7_OO_ .M1NF_YYK_WW_\ 6KG?^$HN?^>47Y'_ !H_
MX2BY_P">47Y'_&CE8'1;IO\ GFO_ 'W_ /6HW3?\\U_[[_\ K5SO_"47/_/*
M+\C_ (T?\)1<_P#/*+\C_C1RL#HMTW_/-?\ OO\ ^M1NF_YYK_WW_P#6KG?^
M$HN?^>47Y'_&C_A*+G_GE%^1_P :.5@=%NF_YYK_ -]__6HW3?\ /-?^^_\
MZU<[_P )1<_\\HOR/^-'_"47/_/*+\C_ (T<K Z-6DW#<B@>H;/]*DK(TWQ!
M'>2+%(GE2-TYR#6O2M8 HHHI %%%% !1110 5R/Q8\.WGBOP#J>E6$$5S=7!
MA"Q3JK1L!,C-N!90PV@Y&1D#'>NNHH \0D^#[^&]8M)[GP_:^--$D:ZFFT33
M[.VM;6TN'2W1)(K::41E=D+ Y<L&D9A]]L<_KGP3\4ZMHL<;Z?IMQ-!HCVT:
M7JK=W$.ZZED6WMKAW'E31PLB+,59=RKT S7T?10!YY#\.(;;X@:WXATO1='T
MN_N+"T^RZE/I\<K+<^;=&Y8JCHY9DEC#,&&[(Y;!%<VOPYN?$WCS57U;PY=:
M+;R6\]K_ &[ITL"27S21JKS,_GO*B K^[AVD+@%CV'L]% &9X:\/VWA70;#2
M+-YI+:SB6&-[B0O(P'=F[FM.BB@"O=?ZZT_ZZG_T!J9)JMK#JUMIKRXO;B"6
MXBBVGYHXVC5VSC P98^"<G=QT.'W7^NM/^NI_P#0&KG_ !+X:U?4/$6E:QH^
MJV6G3V=K=6CQWU@]TLBS/ ^1MFC*D& >N=W;% #]/^)7A74K\6,'B'3O[0-Q
M-:+927"QSM+%*\+J(V(8XDC=00,';D9'-/;XB^%$M9;IO$^C+;0S"WDF.H1;
M$E()$9.[ 8A6X//!]*\QT7X(ZS:^+/%4$VHPQ>'=2U"WU0S?91Y\[C4+F^,2
M,)<Q[&E1"S*VX9*A3G$U[^SO=7UA91/XDA%Q86-MIEI-'8RQ!+>".>-2WEW*
ML92+ALNK*I (V88T >I7'C+0+6^N;.?7--AO+6 W,]O)=QK)%"%W&1E)RJA3
MG<>,<UB:AXD\$>-K?[,?$^GW/V56OMVG:UY,L2(&5Y-\,BLJ@,P)SCDYKD=<
M_9_FUK2-3TEO$A%A=B\F1Y++?<+=7%A)9O([B0*Z!97<1A5YV_-@5J^+/@RW
MB*XU.:UUD:9)=W<MTA2S#^67LH;7;]X9_P!3NR,'YL#! :@#>T?5O!^N:=#X
M5TB\M;ZP.FXB@L)2\7V53Y'RRH<#:1MX;<"/;-9G@WQEX&T?P\;NPOY=*TJ[
MD6Y%]KXN;;[6\JY5EFO #,2J#HS8 7H,57^'?PAF\#>)+G6+C6_[3EG@FB:/
MR)%P9)_.)WR32,<'(^8DXQS5*'X%#2M%T"VTK7KB._TS3WTY[C4C<7T$L;PK
M&Y2%Y_W1^0$!6VCI@C& #LKSXE>$=-EFBN_%.BVLL+;)4FU&%#&W/# MP>#U
M]#5JS\:^'M0C5[77M,N4:22%6AO(W!D1-[H,-]Y4^8CJ!R>*\_T3X 0:%9Z=
M:0ZRTD%C=WERGFVVYV6>T-L%8[^2H.XMCYNF!UI9_@7*GV::RUR&"^MQ$D<L
MU@9$V+8-9N"@E7E@V\'/RD 884 =E9_$[PG?LJQ>(M.!DN?L<7FW"QB>;;&X
M6(L1YN5FB(*9!WCFJ&D_&CP9JT#2C7K.S18_-9KR58D5?-DB!+D[,EHGPN[.
M,''->>V'[,=WIME!:P>+CY*M$SK]A=0QC6U ^Y.N<FU&0^]</PH(W'8LO@/?
MZ7XHT[7[3Q);B^TP.EFDVF,\05GNF/F*)P7.V[89!7E >A(H ]$;QUX:6^^Q
M-XATI;SRS+]G-[%YFP1^:6V[LX\OY\_W>>G-7]'UO3O$%BMYI=_:ZE9L2JW%
MG,LL9(." RDCBO(U_9K@AT-M+BUTF S6\F9[,296+3VLRK O@AMY?'0#Y<8Y
MKT#X>>#9_!&BW%E<:D=3DFN6N-^)0L8*JNQ?-EE?'RY^9VY8XP,  '4T444
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MA<W3LHBFC16C18$F,K#<<)^\2/(S\YQC ) !VGV6'_GDOY4?98?^>2_E4M%
M%)+>+[?,/+7'E)V]WJQ]EA_YY+^5,C_Y"$W_ %RC_F]<)JGQ6ET;QXV@WFEP
MVEAYZ0K?W5T\+3*T(D,D2M$(Y%#$H0LN_*M\OJ =]]EA_P">2_E1]EA_YY+^
M5>0^)_VDK#0]&BO8-!O))9K*34H+>]FCA,UJ+"\NXYE*&3A_L13:P5EW@E>
M#UOAGXH0>*_$EMI]EI5Y'87-K=W,&IW#1B.X$$T4)\M59FP3(3EPA  X.[@
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M;&:VO(A-"H';I@@U;KF_"K-]HG'\&T$_7/']:Z2LFK, HHHI %%%% !1110
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M,!E9&&01P00.QW3?\\U_[[_^M1NF_P">:_\ ??\ ]:@"6BHMTW_/-?\ OO\
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MT,6F-+U!KIKF#S'_ 'AN9)))_FSN&YI9#P1C=Q@ 8U-TW_/-?^^__K4;IO\
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M_P#6H XJ;X(^"[JQ:SGTF2>W,1@"RWUP^R(V\]OY2$R92,174ZA%PJ^82 "
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M]*_3?=-_SS7_ +[_ /K4;IO^>:_]]_\ UJU?$=5[THG,N"Z"VQ$_O1^7]O\
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MM!(%/*/:P%&(SM.6SG;0![)17@OA'X,ZO;:%X.M[BW.F,VG@:[9221S6TES
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MN]7#4H\E[?\  UDKO7L?7'_#=GPK_P"?O5/_   ;_&C_ (;L^%?_ #]ZI_X
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M5/\ P ;_ !K\VJ*O_5O!=Y??_P  S_UVS3M#[G_F?I+_ ,-V?"O_ )^]4_\
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M_P >[C6M6TW2K#P_"VH7VG6>HI]IU$Q0JLUM).ZLXB;!41@#CYMQ)V@5C?\
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M3/\ ON3_  K:HH Q=WB+^YIG_?<G^%&[Q%_<TS_ON3_"MJB@#%W>(O[FF?\
M?<G^%&[Q%_<TS_ON3_"MJB@#%W>(O[FF?]]R?X4;O$7]S3/^^Y/\*VJ* ,7=
MXB_N:9_WW)_A1N\1?W-,_P"^Y/\ "MJB@#%W>(O[FF?]]R?X5'#'XAA0KMTP
MY9F^_)W8GT]ZWJ* ,7=XB_N:9_WW)_A1N\1?W-,_[[D_PK:HH Q=WB+^YIG_
M 'W)_A1N\1?W-,_[[D_PK:HH Q=WB+^YIG_?<G^%&[Q%_<TS_ON3_"MJB@#%
MW>(O[FF?]]R?X4;O$7]S3/\ ON3_  K:HH Q=WB+^YIG_?<G^%&[Q%_<TS_O
MN3_"MJB@#%W>(O[FF?\ ?<G^%&[Q%_<TS_ON3_"MJB@#%W>(O[FF?]]R?X4;
MO$7]S3/^^Y/\*VJ* ,7=XB_N:9_WW)_A1N\1?W-,_P"^Y/\ "MJB@#%W>(O[
MFF?]]R?X4;O$7]S3/^^Y/\*VJ* ,7=XB_N:9_P!]R?X4;O$7]S3/^^Y/\*VJ
M* ,7=XB_N:9_WW)_A1N\1?W-,_[[D_PK:HH Q=WB+^YIG_?<G^%&[Q%_<TS_
M +[D_P *VJ* ,NS;6OM"?:EL!!_%Y+/NZ=LC'6M2BB@ HHHH **** "BBB@
MK'_M'6/^@/&?^WP?_$UL5A>.O&^B_#7P=K/BGQ%>KIVAZ1:O>7ETX)V1H,G
M'+$] HY)( Y- $O]HZQ_T!X__ P?_$T?VCK'_0'C_P# P?\ Q->'K^W)X#T>
M.[E\;:3XE^&,2:3-K=E)XQL([1=3M8]H?[-LE?=+F2("%MLI,B@)DXKIO"/[
M6GPS\8^*9-"@\1V6GW#6>EW=E<:A?6T4.I&_68PPVK>:3+*/(<,H'!( W<X
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MI68U$D*+,SIYQ)4N!LSG[JLW3HI/04 5_P"T=8_Z \?_ (&#_P")H_M'6/\
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M&#_XFMBJEOJ]C=Z8NHP7MO-I[1F47<<JM$4 R6W@XQCOG% %+^T=8_Z \?\
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M@#'_ +1UC_H#Q_\ @8/_ (FC^T=8_P"@/'_X&#_XFMBB@#'_ +1UC_H#Q_\
M@8/_ (FC^T=8_P"@/'_X&#_XFMBB@#'_ +1UC_H#Q_\ @8/_ (FC^T=8_P"@
M/'_X&#_XFMBB@#'_ +1UC_H#Q_\ @8/_ (FC^T=8_P"@/'_X&#_XFMBB@#'_
M +1UC_H#Q_\ @8/_ (FC^T=8_P"@/'_X&#_XFMBB@#'_ +1UC_H#Q_\ @8/_
M (FC^T=8_P"@/'_X&#_XFMBB@#'_ +1UC_H#Q_\ @8/_ (FC^T=8_P"@/'_X
M&#_XFMBB@#'_ +1UC_H#Q_\ @8/_ (FC^T=8_P"@/'_X&#_XFMBB@#'_ +1U
MC_H#Q_\ @8/_ (FC^T=8_P"@/'_X&#_XFMBB@#'_ +1UC_H#Q_\ @8/_ (FC
M^T=8_P"@/'_X&#_XFMBB@#'_ +1UC_H#Q_\ @8/_ (FC^T=8_P"@/'_X&#_X
MFMBB@#'_ +1UC_H#Q_\ @8/_ (FC^T=8_P"@/'_X&#_XFMBB@#,M+W4I;A$G
MTQ((C]Z07(<CCTV\UIT44 %%%% !1110 4444 %>>_M _"*W^/7P7\6^ ;J]
M?34URR:W2\1=WDR AXW*Y&X!U4E<C(!&1G->A44 ?(GQ!_9I^+7[0$<TGQ)U
M3P;8S:5X7UK1M%B\/FYECNK_ %"S-J;RY,L:F)$7D1('P6SN.T9SM2_8W\9^
M(M%\6O?CPE:ZUJVG^#;2S-O/-)':MI5Z9KS$AMU8+)'MVX7YF&&"@9K[,HH
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M47[*&^3GRW7=C^$\KDU2U'X#:]>:I!>-9>';JVC>,G2KFYF%N56PBM@N5A'
M:,L..@7H>GT!10!X3H_P'\1Z?JEC+)K-HTT(@+:^KR_V@BI:>2;=5P%\HO\
M-G<#Z@G!'-ZM\&=?\'Z6^I6=G91:U!#80::-$6>X::\BD??/-F,; Z.^YB<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M $!5_P# M?\ "C^TM7_Z J_^!:_X4"-FBL;^TM7_ .@*O_@6O^%']I:O_P!
M5?\ P+7_  H V:*QO[2U?_H"K_X%K_A1_:6K_P#0%7_P+7_"@#9HK&_M+5_^
M@*O_ (%K_A1_:6K_ /0%7_P+7_"@#9HK&_M+5_\ H"K_ .!:_P"%']I:O_T!
M5_\  M?\* -FBL;^TM7_ .@*O_@6O^%']I:O_P! 5?\ P+7_  H V:*QO[2U
M?_H"K_X%K_A34U?5I&D4:*N4;:?]+7T!]/>@#PG4/C%XRT[1_MT<_P!M@&AW
M4\Y6WCWP3?:9X89P N"%*Q J<C!)(ZFMF\^)6M0^);R&+Q+NOX;W3(;7P_\
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M7BCQ+XAT_3?$)P3H":B76)%2Z\QXVCF! &#M<H5'&Y3Q7LU8W]I:O_T!5_\
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M .!:_P"%']I:O_T!5_\  M?\* -FBL;^TM7_ .@*O_@6O^%']I:O_P! 5?\
MP+7_  H V:*QO[2U?_H"K_X%K_A1_:6K_P#0%7_P+7_"@#9HK&_M+5_^@*O_
M (%K_A1_:6K_ /0%7_P+7_"@#9HK&_M+5_\ H"K_ .!:_P"%']I:O_T!5_\
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MAIICB,*?8[5(ML98N4&T#"[B6QTR2:I3_#GPG=7%I/-X8T::>S)-M))I\3-
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M]..9XN*LJC_ \2>2Y?4DY2I*[]5^3/*_^&?[3_H,3?\ ?@?XT?\ #/\ :?\
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M!K6/#.F:?>3Z7I5U;6$5G;7NGZ>MQ<KKK),"UQ=HD!?=_%]V8Y9LD@55\._
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M,-ET6X/K@\'V/(K2T[QQ'IL>G+"UU#Y+6@G\O \Q(FE+KUY!\Q>#P<'-3_\
M";6&0L$E_IJJ8/WEK&F]UC5@8R"P&WD8SD>JT.-G_!7]?+_,%+F2?UEW]?\
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M=0B^U6L%G]EN+^6>"*.+=L"*[''WL<DX'"[03GLMP]:-P]: %HI-P]:-P]:
M(+[_ %*_]=8__0UKGO'6LWVF_P#"/V6GS+;7&K:K%9M<,%/EQA))I,!A@LR0
ML@SW<'G%=!?,/)7G_EK'_P"AK5+Q%X=M/$UK;0W+R1/:W45Y!-"0'BEC8,K
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MWVFK&_W5NP&F212O:0R%2K=&&>G-CQ-\-8_$7B"XU>+7M7T:YN=/73)UTYH
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MP H517>4FX>M&X>M "U7M?\ 77?_ %U'_H"U/N'K5>U8>==\_P#+4?\ H"T
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M46T?JL)<T5*VYJ_\) __ #ZV_P#WS1_PD#_\^MO_ -\UE45/*BS5_P"$@?\
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MO-8?58-5BU6ZM+FV\V19)4:")-D^"&"[G PPX&.?8:* "BBB@ HHHH ****
M"BBB@ HHHH KZA_QYS?[M<Y\2O"]SXN\.QV5K;6-XZ7,4[6^H.\22*IR0LJ
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M#9/\:V** ,?_ (1F'_G^U+_P-D_QH_X1F'_G^U+_ ,#9/\:V** ,?_A&8?\
MG^U+_P #9/\ &C_A&8?^?[4O_ V3_&MBB@#'_P"$9A_Y_M2_\#9/\:/^$9A_
MY_M2_P# V3_&MBB@#'_X1F'_ )_M2_\  V3_ !H_X1F'_G^U+_P-D_QK8HH
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M#9/\:V** ,?_ (1F'_G^U+_P-D_QH_X1F'_G^U+_ ,#9/\:V** ,?_A&8?\
MG^U+_P #9/\ &C_A&8?^?[4O_ V3_&MBB@#'_P"$9A_Y_M2_\#9/\:/^$9A_
MY_M2_P# V3_&MBB@#%?PM!(C*U[J15A@C[;)_C3O^$9A_P"?[4O_  -D_P :
MV** ,?\ X1F'_G^U+_P-D_QH_P"$9A_Y_M2_\#9/\:V** ,?_A&8?^?[4O\
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M?[4O_ V3_&C_ (1F'_G^U+_P-D_QK8HH Q_^$9A_Y_M2_P# V3_&C_A&8?\
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M\T\6P;O0;WQG\15NYTN+GQ99,=7NH=62Q\.)/#I>GK=.MK+8O]F<W,DD0A+
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M#J5U8>-=9\C2KC44:UM>;:2(%3F7@B1UX]P3WSCNU)Q=TR91C-<LE=%^WOM
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46>,^JDC(Z#IZ5:HHH **** /_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
